Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Save My Fat: Save Your Stem Cells For Future Use, No Matter Your Age.

## Sitemaps
[XML Sitemap](https://savemyfat.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Are Stem Cells Legal in the US? Answering the Most Common Question](https://savemyfat.com/are-stem-cells-legal-in-the-us/): Ask whether stem cells are legal in the United States and you are really asking four questions: about the cells, the products made from them, the procedures physicians perform, and the claims used to sell those procedures. Each has a different answer.
- [Is Stem Cell Therapy Legal in the US? A State-by-State Answer](https://savemyfat.com/is-stem-cell-therapy-legal-us/): Legality and FDA approval are two different questions, and most people searching for one are really asking about the other. Federal law governs stem cell products in every state, and a small group of states have layered their own statutes on top. This guide covers the federal rule, the states with their own laws, and what those laws change.
- [MSC Cells Definition: What Mesenchymal Stromal Cells Actually Are](https://savemyfat.com/msc-cells-definition-stem-cells/): MSC stands for multipotent mesenchymal stromal cells. Many sources still say mesenchymal stem cells, and the difference is not cosmetic. This article covers the definition, the criteria, and the dispute.
- [Stem Cell Banking Cost in the USA: What Actually Drives Pricing](https://savemyfat.com/tissue-banking-cost-usa-pricing/): Patients searching for stem cell banking cost in the USA find wide price ranges and almost no explanation behind them. There is no authoritative public dataset on adipose tissue banking cost in the United States, so the honest answer starts with what drives a price.
- [Minnesota Stem Cell Rules in 2026: What Actually Applies](https://savemyfat.com/minnesota-stem-cell-rules-2026/): Minnesota has no stem cell statute. Searches of Minnesota Statutes and Minnesota Rules return no state law on stem cell therapy advertising or disclosure, so what reaches a provider here is general consumer protection law, physician discipline law, and federal tissue regulation. This guide covers what applies in 2026 and what patients should verify before banking their own adipose tissue.
- [Ohio Stem Cell Regulation in 2026: What Actually Applies](https://savemyfat.com/ohio-stem-cell-regulation-2026/): Ohio does not have a stem cell law. A full text search of the Ohio Revised Code and the Ohio Administrative Code returns no statute or rule on stem cell therapy, advertising, or disclosure. That absence is the story. This guide covers the Ohio law that does apply, how Ohio compares with Georgia and Tennessee, and the federal rules reaching every provider.
- [Understanding Texas Stem Cell Regulation: What Patients and Providers Should Know in 2026](https://savemyfat.com/texas-stem-cell-law-2026-guide/): Texas has a stem cell statute, and it is narrower than most summaries suggest. Health and Safety Code Chapter 1003, expanded by House Bill 810 in 2017, sets conditions on access to investigational adult cell products rather than permission to sell them. This guide covers what the Texas law says, what it does not, how it compares with the newer Georgia and Tennessee statutes, and which federal rules apply regardless.
- [Dallas, Texas Adipose-Derived Stem Cell Banking: A Regulatory Overview for Patients](https://savemyfat.com/dallas-texas-stem-cell-banking-rules/): Dallas patients researching adipose tissue banking often find Texas stem cell law first and assume it governs storage. It does not. Texas Health and Safety Code Chapter 1003 sets access and consent rules aimed at physicians, while federal regulation decides how stored tissue is classified. Banking preserves a patient's own tissue. It is not a treatment.
- [Cumming, Georgia Adipose Tissue Banking: Local Patient FAQ](https://savemyfat.com/cumming-georgia-tissue-banking-faq/): People in Cumming ask the same practical questions about adipose tissue banking as everyone else. They want to know where the tissue goes, what Georgia law asks of the provider, and what storage costs each year. This guide answers them and links the sources.
- [Austell, Georgia Adipose-Derived Stem Cell Banking Explained](https://savemyfat.com/austell-georgia-adipose-banking-explained/): Austell residents ask practical questions about adipose banking: what it involves, who has to be part of it, and what Georgia's new stem cell law changed on July 1, 2026. Here are plain answers.
- [Jasper, Georgia Adipose Tissue Banking: A Patient Education FAQ](https://savemyfat.com/jasper-georgia-tissue-banking-faq/): Jasper residents ask the same practical questions about adipose tissue banking as anyone else: what it is, whether distance from Atlanta matters, what Georgia law requires, and what it costs. Banking preserves a patient's own tissue. It is not a treatment.
- [Augusta, Georgia Adipose-Derived Stem Cell Banking: How to Check a Local Provider](https://savemyfat.com/augusta-georgia-stem-cell-banking-provider-checks/): Augusta residents researching adipose tissue banking have more to check than a price sheet. Georgia's stem cell law now sets disclosure duties for clinicians, federal rules govern the facilities that handle tissue, and the FTC sets the evidence bar for health claims.
- [Carrollton, Georgia: Understanding Adipose-Derived Stem Cell Banking Options](https://savemyfat.com/carrollton-georgia-stem-cell-banking-options/): Carrollton sits in Carroll County, about 40 miles west-southwest of Atlanta in a straight line. Residents there often ask whether that distance narrows their options for adipose tissue banking, and whether Georgia's stem cell law reads differently outside the metro core. It does not. This guide covers the federal rules that apply everywhere, the state statute that took effect in 2026, what the process involves, and the questions worth putting to a physician.
- [Roswell, Georgia Adipose Tissue Banking: Eligibility and Process Overview](https://savemyfat.com/roswell-georgia-adipose-banking-eligibility/): Roswell is a city of 91,505 people spanning Fulton and Cobb counties, about 20 miles northeast of Atlanta. Residents asking about adipose banking want three answers: who qualifies, what happens before collection, and what they sign.
- [Marietta, Georgia Adipose Tissue Banking: What Local Patients Need to Know](https://savemyfat.com/marietta-georgia-tissue-banking-guide/): If you live in Marietta and want to know whether adipose tissue banking is available to you, the answer is yes. The harder question is who gets regulated, and how. Georgia's stem cell law took effect on July 1, 2026, and it changed what local clinicians must tell you first. It approved no therapy.
- [A Year in Adipose-Derived Stem Cell Research: What August 2026 Readers Should Know](https://savemyfat.com/adipose-stem-cell-research-2026-year-in-review/): Any honest adipose stem cell research year in review has to hold two facts at once. The rules on how clinics advertise, consent, and source cells changed sharply. The evidence that adipose-derived cells help patients did not.
- [Sterility and Safety Testing: What Happens to Banked Tissue Before It Is Approved for Storage](https://savemyfat.com/sterility-testing-adipose-tissue-banking/): Before a sample of adipose tissue enters long-term storage, a laboratory has to answer three narrow questions. Is it sterile. Is it free of bacterial endotoxin. Is it free of mycoplasma. Sterility testing in adipose tissue banking is not one assay but a release panel, and each part carries its own method, its own clock, and its own pass or fail line.
- [The Full List of Adipose-Derived MSC Clinical Trials Recruiting Patients in Late 2026](https://savemyfat.com/adipose-msc-trials-recruiting-2026/): This is the set of adipose MSC trials recruiting in 2026, returned by one ClinicalTrials.gov search, filtered to recruiting status, as of late July 2026. Ten studies appear, spread across knee osteoarthritis, neurologic conditions, and several other areas. Six of the ten sit in Phase 1 or Phase 1/2. Recruiting means a study is open for enrollment, and it means nothing beyond that.
- [Warning Signs Specific to Regenerative Medicine Clinics Treating Chronic Pain](https://savemyfat.com/chronic-pain-clinics-warning-signs-regenerative/): Chronic pain is the largest target market for unapproved regenerative offerings, and the reason is structural. Pain is subjective, it fluctuates on its own, and it responds strongly to expectation, which makes almost any intervention look like it worked. The warning signs at regenerative medicine clinics treating chronic pain are document questions, not medical ones.
- [How Can Patients Verify Whether Stem Cell ED Clinics Are Legitimate and Properly Regulated](https://savemyfat.com/stem-cell-clinics-verification-ed-legitimate/): How can patients verify whether stem cell clinics offering ED procedures are legitimate? Most of the answer sits in free public records, and the work takes about an evening. This guide covers five checks you can run before paying: the FDA warning letters database, the FDA list of approved cellular and gene therapy products, the FDA consumer alert, the status field on ClinicalTrials.gov, and the written notice your state law may require.
- [Psychiatrist and Behavioral Health Guide to Adipose Banking Conversations](https://savemyfat.com/psychiatrist-adipose-banking-conversations/): Behavioral health clinicians are often the first person a patient tells about a regenerative medicine decision, and the only one who hears the hope attached to it. This psychiatrist adipose banking guide is about that conversation rather than about cells, and about how to explore a patient's expectations without dismissing them.
- [OB-GYN Guide to Adipose Banking: What Patients Are Asking](https://savemyfat.com/ob-gyn-adipose-banking-guide/): Patients bring adipose banking into gynecology visits after seeing it advertised, and the questions rarely start with the biology. This OB-GYN adipose banking guide works through the questions that actually arrive in the exam room and gives a defensible answer to each. The framing throughout is storage and regulation, because that is where the verified ground sits.
- [Endocrinologist Guide to Adipose Banking: Beyond the Metabolic Health Overview](https://savemyfat.com/endocrinologist-adipose-banking-guide/): Adipose tissue is an endocrine organ, which gives an endocrinologist a professional interest in what happens when a patient banks a sample of it. This endocrinologist adipose banking guide covers the secretory biology, the collection variables that move cell yield, and the federal criteria governing the material after it leaves the patient.
- [Urologist Guide to Adipose Banking and the Erectile Dysfunction Research Landscape](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/): Erectile dysfunction is one of the most aggressively marketed indications in regenerative medicine, and the marketing is usually what brings erectile dysfunction research questions into the office. This urologist adipose banking guide sets out the federal, advertising, and state law picture needed to answer a patient who arrives having already seen an advertisement. It deliberately does not summarize individual studies.
- [Dermatologist Guide to Adipose Banking: What the Research Landscape Looks Like in 2026](https://savemyfat.com/dermatologist-adipose-banking-guide/): Aesthetic medicine carries the heaviest marketing risk in the regenerative space. This dermatologist adipose banking guide maps the line between an established surgical procedure and an unapproved biological drug, a line drawn by processing and by advertising rather than by specialty. It also covers what recent FDA enforcement turned on and what the FTC expects.
- [What Happens If a Clinical Trial for Adipose-Derived Cells Is Terminated Early](https://savemyfat.com/terminated-clinical-trial-what-it-means/): Seeing a terminated clinical trial feels like a verdict on the science, and it usually is not one. Termination is a registry status with a narrow definition and a required public explanation. This article covers what stopping early involves and what the label does not tell you.
- [The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/): Families researching multiple system atrophy clinical trials 2026 usually find one study and assume the field is in motion. The verified record is smaller and quieter. This guide reads the Mayo Clinic registry page as written, lists the four other registered cell therapy studies in MSA, and explains why they cannot be combined into one conclusion.
- [Ryoncil in 2026: What Changed Since the First FDA-Approved MSC Therapy](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/): In December 2024 the FDA licensed the first mesenchymal stromal cell therapy sold in the United States. This Ryoncil update 2026 covers what changed in the roughly 20 months since, and what did not. The label reads the same today. The marketing built around it does not.
- [NCT06002841 Explained: What This Registered Clinical Trial Is Studying](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/): NCT06002841 appears in searches about adipose research and cell therapy, and it is rarely what the searcher expects. The record describes a small Brazilian study of mesenchymal-cell-derived extracellular vesicles in acute respiratory failure, and its status has read Unknown since 2023. This post walks that record field by field.
- [How Tissue Banks Validate Regulatory Compliance: A Behind-the-Scenes Look](https://savemyfat.com/tissue-bank-compliance-validation/): How do tissue banks validate regulatory compliance? Tissue bank compliance is not one certificate. It is four separate layers that each produce different paperwork. This guide walks through federal registration, the quality system behind Current Good Tissue Practice, lot release testing, and the accreditation bodies that state legislatures started writing into statute in 2025 and 2026.
- [Does ClinicalTrials.gov Include Failed Phase 3 Trials? What Patients Should Understand](https://savemyfat.com/failed-clinical-trials-clinicaltrials-gov/): Does ClinicalTrials.gov include failed clinical trials? Yes, and federal rules keep those records public permanently. This guide covers the law behind that permanence, decodes the status words patients misread most, and walks through a real terminated Phase 3 record.
- [Cartilage Regeneration Research in 2026: A Patient’s Guide to What Is Being Studied](https://savemyfat.com/cartilage-regeneration-research-2026/): Cartilage regeneration research in 2026 is an active field, and the published results so far are mixed. The largest randomized, placebo-controlled trial of adipose-derived cells for knee osteoarthritis reported a negative primary endpoint, with the placebo group scoring numerically better. This guide covers that trial, the studies still running, and what "being studied" does and does not mean.
- [Autologous Versus Allogeneic Cell Sources: Why the Distinction Shapes Regulatory Pathways](https://savemyfat.com/autologous-vs-allogeneic-cell-sources/): The difference between autologous vs allogeneic stem cells sits at the center of federal tissue regulation. One word can decide whether a product is regulated solely as a 361 human cell and tissue product or travels the longer biologic route. Two 2026 state laws now draw that same line.
- [What Cell Passage Number Means and Why It Matters for Any Future Research Use](https://savemyfat.com/passage-number-mesenchymal-stem-cells/): Researchers label cultured cells with a passage number, and patients rarely learn what it means. Cell passage number for mesenchymal stem cells counts how many times a population has been expanded in a lab, not how old the donor is. This guide explains the term and the evidence.
- [Enzymatic Versus Mechanical Isolation: How Adipose Stem Cells Are Actually Separated From Fat](https://savemyfat.com/enzymatic-isolation-adipose-stem-cells/): Laboratories separate cells from fat in two ways. Enzymatic isolation of adipose stem cells uses collagenase to digest the tissue matrix. Mechanical isolation of adipose tissue uses shaking, shearing, and spinning instead. The two approaches produce very different cell counts, and they sit in very different places under federal tissue regulation. Here is what the published data shows, and why the method decides the legal category of what comes out.
- [How Adipose Tissue Yields More Stem Cells Per Gram Than Bone Marrow: The Published Numbers](https://savemyfat.com/stem-cell-yield-adipose-vs-bone-marrow/): The claim that fat holds more stem cells than bone marrow gets repeated constantly, almost always with no citation attached. This article puts the published figures for adipose tissue stem cell yield vs bone marrow in one place, each with its study and year, alongside the strongest counterargument in the literature.
- [CD105, CD73, and CD90: What Surface Marker Testing Reveals About Banked Cells](https://savemyfat.com/surface-marker-testing-cd105-cd73-cd90/): Laboratories identify mesenchymal stem cells by the proteins on the outside of the cell membrane. CD105, CD73, and CD90 form the positive side of the standard panel, and a second list of markers has to be nearly absent. This guide covers what surface marker testing measures and where its limits sit.
- [The ISCT Minimal Criteria: How Scientists Actually Define a Mesenchymal Stem Cell](https://savemyfat.com/isct-minimal-criteria-mesenchymal-stem-cells/): The ISCT minimal criteria are the three-part definition researchers apply before calling a cell a mesenchymal stromal cell. They were published in 2006 so that results from different laboratories could be compared. This article quotes all three criteria, gives the numeric thresholds, and explains what they do not establish.
- [What Trilineage Differentiation Means and Why It Defines a True Mesenchymal Stem Cell](https://savemyfat.com/trilineage-differentiation-mesenchymal-stem-cells/): Trilineage differentiation in mesenchymal stem cells is the functional test that separates a real stem cell population from ordinary connective tissue cells that look identical in a flask. It asks whether one population can become bone, fat, and cartilage cells in a dish. This guide covers the three assays, the stains and biomarkers behind each, and the hard limit on what a passing result means.
- [FDA’s CMC Flexibility Guidance for Cell and Gene Therapy: What Changed in 2026](https://savemyfat.com/fda-cmc-flexibility-cell-and-gene-therapy-2026/): FDA CMC flexibility for cell and gene therapy in 2026 reached the public in two separate events, and the confusion comes from treating them as one. January 11, 2026 brought a press announcement. The guidance document itself is dated May 2026. This article separates the two and explains the limits of what it permits.
- [The Multi-State Stem Cell Law Map Update: What Changed Since June 2026](https://savemyfat.com/state-stem-cell-laws-2026-map-update/): Three state stem cell statutes took effect on July 1, 2026, and a fourth bill was vetoed eleven days earlier. This multi-state stem cell law map 2026 update covers the state stem cell laws that changed and adds Utah's quieter May amendment, verified against official sources.
- [How Advertising Disclosure Rules Differ Across Georgia, Arizona, and Tennessee](https://savemyfat.com/stem-cell-advertising-disclosure-law-comparison/): Georgia and Tennessee wrote a mandatory patient notice into provider advertising in 2026. Arizona passed a similar bill and lost it to a veto. Any honest stem cell advertising disclosure law comparison has to account for all three outcomes, because the third one is a blank space that marketing teams keep filling in with assumptions.
- [The Stem Cell Therapeutic and Research Reauthorization Act of 2026: What S. 4109 Covers](https://savemyfat.com/stem-cell-reauthorization-act-s-4109/): The Stem Cell Therapeutic and Research Reauthorization Act of 2026, usually shortened to the Stem Cell Reauthorization Act, moved twice this summer, and patients keep asking whether it changes anything for adipose tissue. It does not. S. 4109 is still pending, and the two programs it would extend involve donated bone marrow and umbilical cord blood, not fat.
- [Arizona’s Proposed Stem Cell Therapy Act: What SB 1214 Would Require](https://savemyfat.com/arizona-stem-cell-bill-sb-1214-vetoed/): The Arizona stem cell bill known as SB 1214 passed both chambers of the Legislature in 2026 and then stopped. Governor Katie Hobbs vetoed it on June 19, 2026, and no override followed. Arizona has no stem cell disclosure or consent statute today. This article covers what the bill would have required and what applies instead.
- [Tennessee’s New Stem Cell Framework: What House Bill 2246 Means for Physicians](https://savemyfat.com/tennessee-stem-cell-law-house-bill-2246/): Tennessee House Bill 2246 is no longer a proposal. It became Public Chapter 1016 and took effect on July 1, 2026. The Tennessee stem cell law approves nothing. It sets notice, consent, sourcing, and reporting duties for physicians who offer stem cell or regenerative medicine therapies in the state.
- [Georgia’s New Stem Cell Therapy Law: What House Bill 1275 Changes for Providers](https://savemyfat.com/georgia-stem-cell-law-house-bill-1275/): The Georgia stem cell law took effect on July 1, 2026, changing how licensed providers advertise, document, and source cell therapies the FDA has not approved. House Bill 1275 became Act 453 on May 11, 2026, creating O.C.G.A. 43-34-49. This guide covers what the statute requires, how it differs from Florida's law, and where adipose fits.
- [Adipose Banking for Families: What Couples and Parents Need to Know in 2026](https://savemyfat.com/adipose-banking-families-couples-and-parents-2026/): TLDR: Under federal tissue rules, banked adipose tissue may potentially be used for the person who banked it or, in some cases, for first-degree or second-degree blood relatives, which is what family eligibility refers to. Couples banking together each preserve their own tissue, since spouses are not blood relatives for this purpose. Banking for a minor is a decision for parents and the child's physician, with appropriate consent. None of this changes the core fact that banking is preservation, not treatment, and no adipose-derived product is FDA-approved for disease treatment. Banking adipose tissue preserves a person's own tissue under 21 CFR Part 1271; it does not guarantee eligibility, access, or clinical benefit.
- [Adipose Banking Pricing: What You Actually Pay For](https://savemyfat.com/adipose-banking-pricing-what-you-actually-pay-for/): Patients researching adipose banking want to understand what the price covers before they commit. Transparent, itemized pricing is one of the clearest signs of a legitimate banking service, and understanding the components helps a patient evaluate any offer. This guide breaks down what the price covers across the harvest, lab processing, storage, and future access, without quoting figures that should be confirmed on the current pricing page.
- [Sports Medicine Physician Guide to Adipose Banking in 2026](https://savemyfat.com/sports-medicine-physician-guide-to-adipose-banking/): Sports medicine physicians work with active patients who have long health horizons and an interest in musculoskeletal care, which makes adipose banking a topic worth understanding accurately. With Wyoming's law now in effect alongside Florida's, the state landscape has shifted, while the musculoskeletal evidence remains more sobering than marketing suggests. This guide covers the law, the evidence as it actually stands, athlete-specific considerations, and the operational details.
- [How Save My Fat Works With Your Physician: A Patient Guide](https://savemyfat.com/how-save-my-fat-works-with-your-physician-your-guide/): Patients are sometimes unsure whether Save My Fat is a medical provider, a lab, or something else, and where their own physician fits in. The answer involves three distinct roles working together: Save My Fat coordinates the preservation service, a physician performs the harvest and maintains the medical relationship, and a U.S.-based tissue bank processes and stores the tissue. This guide explains each role and what a patient does at every step.
- [Adipose Banking for Multiple Sclerosis Patients: What to Know](https://savemyfat.com/adipose-banking-for-multiple-sclerosis-patients/): Patients with multiple sclerosis and their families often ask whether banking adipose tissue is relevant and what the research shows for MS. The honest answers keep banking framed as preservation, keep the research framed as early and investigational, and place the decision with the treating neurologist or MS specialist. This guide explains what the research is studying, how disease activity factors in, and what to ask. For the basics of the service, the complete guide to adipose tissue banking explains what banking preserves and why.
- [Multi-State Stem Cell Law Updates: What Changed on July 1, 2026](https://savemyfat.com/multi-state-stem-cell-law-updates-july-1-2026/): On July 1, 2026, Wyoming's Stem Cell Freedom Act took effect, adding another state to the patchwork of laws governing non-FDA-approved stem cell therapy. For physicians tracking this landscape, the practical questions are what actually changed, what stayed the same, and what none of these laws do. This update covers the July 1 change, the current five-state framework, and the federal rules that remain unchanged.
- [What Informed Consent for Adipose Banking Actually Covers](https://savemyfat.com/what-informed-consent-for-adipose-banking-covers/): Patients are often asked to sign a consent form right before banking, and many sign without fully understanding what they are agreeing to. This guide explains what a banking consent form should and should not say, the elements a legitimate form contains, the state disclosure laws a patient may encounter, and the red flags that signal a problem. Reading this before signing helps a patient consent with genuine understanding.
- [Adipose Banking for Parkinson’s Disease Patients: What to Know Before You Decide](https://savemyfat.com/adipose-banking-for-parkinsons-disease-patients/): Patients with Parkinson's disease and their caregivers often ask whether banking adipose tissue is relevant, what the research shows, and whether disease progression affects the decision. The honest answers keep banking framed as preservation, keep the research framed as early and investigational, and place the decision with the treating neurologist. This guide explains what the research is studying, how progression affects timing, and what to ask.
- [What Questions to Ask Your Doctor About Banking Adipose Tissue](https://savemyfat.com/questions-to-ask-your-doctor-about-banking-adipose/): Deciding whether to bank adipose tissue is easier when a patient walks into the conversation with the right questions. This guide organizes twenty specific questions by category, each with a brief note on why it matters, so a patient can have a thorough, informed discussion with their physician. It does not tell a patient what answers to expect, because those depend on individual circumstances and the specific provider.
- [GP and Concierge Medicine Physician Guide to Adipose Banking](https://savemyfat.com/gp-concierge-medicine-physician-guide-adipose-bank/): Concierge and direct primary care physicians occupy a distinctive position: longstanding patient relationships, wellness-oriented panels, and cash-pay comfort. That combination makes adipose banking a plausible addition to some practices, but only if it is offered honestly as a preservation service rather than sold as a therapy. This guide is written for physicians who are skeptical of vendor pitches and want a measured account of how banking fits, what the physician actually does, and where the compliance lines are.
- [Adipose Banking for Longevity Medicine Patients in 2026](https://savemyfat.com/adipose-banking-for-longevity-medicine-patients-2026/): Patients in longevity medicine, healthy-aging programs, and biohacking communities often ask how banking adipose tissue fits their broader approach. The honest answer treats banking as a preservation decision rather than a longevity intervention, and it keeps the rationale grounded in what the research actually supports. This guide explains why some longevity-focused patients bank, what aging does to adipose-derived cells, and how to think about timing without overstating what banking offers.
- [What Happens to Your Adipose Tissue: A Patient Guide](https://savemyfat.com/what-happens-to-your-adipose-tissue-patient-guide/): After a banking collection, a reasonable question is what actually happens to the tissue. This guide walks through the journey from the collection site to long-term storage at a U.S.-based tissue bank in plain language, so a patient understands each step. It describes the process for banking intact adipose tissue, which is what Save My Fat preserves, and it is transparent about what a patient should confirm before relying on any specific detail.
- [How to Verify a Stem Cell Banking Company Before You Pay](https://savemyfat.com/how-verify-stem-cell-banking-company-before-you-pay/): Before paying any company to bank adipose tissue, a patient should be able to verify its claims against public, independent sources. The tissue banking field includes serious operators and questionable ones, and the difference is checkable. This guide gives a practical verification process: what to confirm, where to confirm it, and the marketing language that should make a patient pause.
- [Wound Care Physician Guide to Adipose Banking Integration](https://savemyfat.com/wound-care-physician-guide-to-adipose-banking/): Wound care and hyperbaric medicine physicians have a specific stake in the regenerative-medicine conversation, because wound care is one of three areas named in Florida's stem cell law. That has prompted interest in whether banking a patient's own tissue fits a wound care practice. This guide reads the law accurately, separates banking from therapy, and lays out the research, logistics, and documentation that responsible integration requires.
- [Adipose Banking and Chronic Kidney Disease: What Patients Should Know](https://savemyfat.com/adipose-banking-and-chronic-kidney-disease/): Patients with chronic kidney disease sometimes ask whether banking adipose tissue is relevant to their condition. The honest answer requires separating genuine but early research from any suggestion that banking treats kidney disease. This guide explains what the kidney-related adipose research is actually studying, how CKD stage factors into a banking decision, and why the conversation belongs with a nephrologist. For the basics of the service, the complete guide to adipose tissue banking explains what is preserved and why.
- [Adipose Banking for Cancer Survivors: What to Know Before You Decide](https://savemyfat.com/adipose-banking-cancer-survivors-what-to-know/): Cancer survivors and patients in remission often ask whether they can bank adipose tissue and whether prior treatment has affected their cells. These are reasonable questions, and the honest answers depend heavily on individual medical history and an oncologist's input. This guide explains what the research suggests about treatment effects on cell quality, what remission timing means, and why this decision belongs in a conversation with the treating oncology team.
- [Rheumatologist Guide to Adipose Banking and the Autoimmune Research Pipeline](https://savemyfat.com/rheumatologist-guide-adipose-banking-and-autoimmune/): Rheumatologists managing lupus, rheumatoid arthritis, and related conditions encounter growing patient interest in stem cells, often framed around immune modulation. This guide gives an accurate read of the autoimmune adipose-derived pipeline, addresses how active disease and treatment affect banking considerations, and frames the patient conversation honestly for an RA or lupus patient.
- [Metabolic Health Physicians: Adipose Banking, Diabetes, and the Endocrine Pipeline](https://savemyfat.com/metabolic-health-adipose-banking-diabetes-endocrine/): TLDR: Adipose tissue is an active endocrine and immune organ, a fact metabolic physicians already work with, and adipose-derived stem cells are under early study in metabolic and endocrine research. Obesity and metabolic dysfunction are associated with changes in adipose tissue and its cells, so cell quality is a legitimate consideration when discussing banking timing, though individual outcomes cannot be predicted. No adipose-derived product holds FDA approval for any metabolic condition. Banking preserves a patient's own tissue under 21 CFR Part 1271; it is not a treatment for diabetes or metabolic disease, and it does not guarantee eligibility, access, or clinical benefit.
- [Cardiologist Guide to Adipose Banking and the Heart Failure Research Pipeline](https://savemyfat.com/cardiologist-guide-to-adipose-banking-and-heart/): Cardiologists managing heart failure increasingly field questions about stem cells, and some are weighing whether to introduce banking to patients. This guide gives an accurate read of the cardiac adipose-derived pipeline, explains why the most cited trial does not support autologous banking, and addresses how heart failure's long disease course changes the banking conversation compared with rapidly progressive conditions.
- [Right to Try vs. Expanded Access: What Patients Actually Need to Know](https://savemyfat.com/right-to-try-vs-expanded-access-you-need-to-know/): Patients researching options beyond approved care often encounter two terms, Right to Try and expanded access, and assume they are interchangeable shortcuts to investigational therapy. They are neither interchangeable nor shortcuts. This guide explains what each actually requires, how they compare with a clinical trial, and why banking a person's own tissue fits neither pathway directly while still preserving optionality.
- [What Expanded Access Really Means for Patients Who Have Banked Their Tissue](https://savemyfat.com/what-expanded-access-means-for-patients-banked-cells/): Patients who have banked adipose tissue often ask a reasonable next question: does expanded access give a way to use it? This guide explains what expanded access actually is, what it is not, and why banking a person's own tissue does not by itself open an expanded access pathway. The goal is a clear, honest picture so expectations match reality.
- [Neurologist Guide to Adipose Banking and the 2026 Trial Pipeline](https://savemyfat.com/neurologist-guide-adipose-banking-2026-pipeline/): Neurologists managing progressive conditions such as ALS, multiple system atrophy, Parkinson's disease, and traumatic brain injury increasingly encounter patients asking about stem cells and whether to bank their own tissue. This guide gives clinicians an accurate read on the adipose-derived trial pipeline, the procedural timing questions that come up in neurology, and how to introduce banking to a patient without creating false expectations.
- [Dermatologist Guide: Adipose Banking, Hair Restoration, and the Skin Research Pipeline](https://savemyfat.com/guide-adipose-banking-hair-skin-research-pipeline/): Dermatologists are fielding more patient questions about adipose-derived stem cells, usually prompted by marketing around hair restoration and inflammatory skin conditions. This guide gives clinicians a grounded read on what the research pipeline actually contains, how banking differs from the products being studied, and how to fit a preservation service into a dermatology practice without overstating what it offers.
- [Plastic Surgeon Guide: Banking Adipose Tissue During Liposuction](https://savemyfat.com/surgeon-guide-banking-adipose-tissue-liposuction/): Plastic surgeons who perform liposuction already access the tissue that adipose banking preserves, which makes them a natural collection partner. The questions are operational: how to divert a portion of lipoaspirate for banking, what consent and chain-of-custody require, and where the relevant state law does and does not apply. This guide walks through the workflow without overstating what banking offers.
- [Pain Management Physicians and Adipose Banking in 2026](https://savemyfat.com/pain-management-physicians-and-adipose-banking-2026/): Pain management physicians occupy a specific place in the regenerative-medicine conversation, because pain management is one of the three therapy areas named in Florida's stem cell law. That has prompted interest in whether banking a patient's own tissue fits a pain practice. This guide separates the two activities, reads the law accurately, and lays out the logistics, patient framing, and documentation that responsible integration requires.
- [Orthopedic Surgeon Guide to Adipose Banking Integration](https://savemyfat.com/orthopedic-surgeon-guide-to-adipose-banking-int/): Orthopedic surgeons are increasingly asked about adipose-derived stem cells, and recent state legislation in Florida and Wyoming has sharpened interest in how a banking service might fit a practice. This guide gives the operational picture: what those laws actually do, what the musculoskeletal evidence honestly shows, how a harvest integrates into existing procedures, and the compliance steps that come before a first banking patient.
- [Atopic Dermatitis and Adipose Stem Cells: What Patients Need to Know](https://savemyfat.com/atopic-dermatitis-and-adipose-stem-cells/): Atopic dermatitis, the chronic inflammatory skin condition many people call eczema, can be stubborn, and patients whose symptoms resist standard options often go looking for what is next in research. Adipose-derived stem cells appear in that search, usually tied to terms like secretome and immune modulation. This guide explains what the research is genuinely studying, and why banking adipose tissue is a separate matter from the donor-cell trials that dominate this field.
- [Hair Restoration and Adipose Stem Cells: What Patients Should Know](https://savemyfat.com/hair-restoration-and-adipose-stem-cells-what-to-know/): Hair loss research has drawn attention to adipose-derived stem cells, and patients searching for options often come across the connection between fat-derived cells and the hair follicle. The practical questions are reasonable: what is the science actually studying, and does banking adipose tissue have anything to do with future hair restoration? This guide walks through what the research shows, framed around a patient's decision rather than any promise that banking grows hair.
- [Adipose Tissue Banking and Autoimmune Disease: What Patients Need to Know](https://savemyfat.com/adipose-tissue-banking-and-autoimmune-diesease/): Patients living with lupus, rheumatoid arthritis, multiple sclerosis, or other autoimmune conditions often ask whether banking adipose tissue makes sense for them, and whether their diagnosis changes the picture. The questions are practical: is banking even possible with active disease, and what is the research actually studying? This guide walks through what is known, framed around a patient's decision rather than any promise of benefit.
- [Adipose Tissue Banking for Women: Hormones, Aging, and Why Timing Matters](https://savemyfat.com/adipose-tissue-banking-for-women-hormones-aging-time/): Women researching adipose tissue banking often arrive with a specific lens: how do hormones, perimenopause, and aging factor into the decision? Fat is not inert padding. It is a hormonally active tissue that changes across the lifespan, and those changes are part of why timing comes up. This guide explains the role of fat as an endocrine organ, how hormonal shifts affect adipose tissue, and what to weigh with a physician.
- [What Age Is Best to Bank Adipose Tissue](https://savemyfat.com/what-age-is-best-to-bank-adipose-tissue/): Many people considering adipose tissue banking ask a simple question: is there a right age to do it, and have they already missed the window? The honest answer is that age is one factor among several, not a strict cutoff. This guide explains how cell quality relates to age, what published research suggests about adipose stem cell yield over time, and the practical questions worth raising with a physician before deciding.
- [What to Document When a Patient Asks About Stem Cell Banking: A Physician’s Compliance and Charting Guide](https://savemyfat.com/what-to-document-when-paitent-wants-bank-stem-cells/): As stem cell banking becomes more visible in the consumer space, primary care physicians and general practitioners are increasingly fielding patient questions they did not seek out. The physician's role here is not to sell banking; it is to keep the conversation compliant, document it, and direct the patient to appropriate resources. Handled well, this is a routine clinical exchange with a clear documentation footprint. Handled poorly, it can create an FTC substantiation problem or leave a physician without a record of the balanced guidance they actually provided. What follows answers three questions: what to say, what to document, and where to refer.
- [Sports Medicine Physicians and Stem Cell Banking: Documentation, State Scope, and the Trial Pipeline Before July 1](https://savemyfat.com/sports-medicine-physicians-and-stem-cell-banking/): Sports medicine is the specialty where the banking conversation arises most naturally. Patients are often young, healthy, and motivated to protect physical function over a long horizon, and they already understand PRP and biologic approaches, so the conceptual distance to banking is short. Two state frameworks bear directly on the specialty: Florida SB 1768 has authorized orthopedic applications since July 1, 2025, and Wyoming SF 48 takes effect July 1, 2026. What follows is a sports medicine physician's brief on the state-law scope, an honest read of the musculoskeletal trial pipeline, the patient conversation, and the documentation a banking program requires.
- [Plastic Surgeons and Adipose Banking: The Harvest Documentation and Informed Consent Checklist](https://savemyfat.com/plastic-surgeons-adipose-banking-informed-consent/): Plastic surgeons already harvest adipose tissue at higher volume than any other specialty, through liposuction, lipoaspirate collection for fat grafting, and body contouring. For them, adding banking is a workflow modification rather than a new procedure: tissue that is already being removed is diverted to a banking container instead of discarded. The incremental procedural burden is minimal; the real work is in documentation and consent. What follows is a practical, compliance-grounded guide to integrating banking into an existing harvest workflow, including the two-consents rule, the harvest documentation set, HIPAA considerations specific to aesthetic practices, and the Florida scope limit that plastic surgeons in particular need to understand.
- [What the Post-Thaw Viability Report Means and Why Florida SB 1768 Requires It](https://savemyfat.com/post-thaw-viability-report-florida-1768-requirements/): Florida SB 1768 requires that before stem cells are used in a patient, the physician receive and review a post-thaw viability analysis report from the accredited facility. It is one of the most operationally specific obligations in the statute, and it is frequently misunderstood as a one-time formality rather than a per-use prerequisite. What follows is a physician-level account of what the report is, what it must contain, when it must be received and reviewed, what to do when viability falls below threshold, and how the report functions as the quality readout on the entire upstream banking process.
- [Chain of Custody for Adipose Tissue: What Physicians Must Document from Harvest to Storage](https://savemyfat.com/chain-of-custody-for-adipose-tissue-what-to-know/): Chain of custody is what turns a banked sample into a usable asset. A unit of adipose tissue that cannot be traced, with documentary certainty, from a specific patient through harvest, transfer, processing, and storage is a unit that a trial sponsor or treating physician may be unable to accept, regardless of how well it was actually preserved. Under 21 CFR Part 1271, that traceability is not a best practice but a core CGTP requirement, and Florida SB 1768 layers state requirements on top that presuppose it. What follows is a physician-level, CFR-cited walkthrough of the six links in the adipose tissue chain of custody, the record-retention rules, what an FDA inspection examines, and an audit-ready checklist.
- [Right to Try vs. Expanded Access: The Critical Differences Every Physician Must Know](https://savemyfat.com/right-to-try-vs-expanded-access-critical-difference/): Since the federal Right to Try Act was signed in 2018, the two pathways for reaching investigational therapies outside a clinical trial, Right to Try and expanded access, have often been treated as interchangeable. They are not. They differ in legal basis, FDA involvement, IRB requirements, eligibility standards, and the protections each affords, and those differences matter when the therapy in question is an investigational cell therapy. What follows is a clear comparison and a practical guide to which pathway fits which patient scenario.
- [The Physician’s Guide to Expanded Access: How to Submit a Single-Patient IND Application](https://savemyfat.com/physicians-guide-expanded-access-how-to-submit-ind/): When a patient with a serious or life-threatening condition cannot enroll in a clinical trial, FDA's expanded access framework is the pathway that can authorize use of an investigational therapy outside a trial. For cell therapies specifically, the single-patient IND is the most commonly used route, and it is also the downstream mechanism that can connect previously banked autologous tissue to authorized use. What follows is a practical walkthrough of the single-patient IND process under 21 CFR Part 312, Subpart I, including where banked tissue fits and the mistakes that most often delay an application.
- [Heart Failure and Adipose Stem Cells: The Phase II Evidence Physicians Are Watching](https://savemyfat.com/heart-failure-and-adipose-stem-cells-phase-2-watched/): Heart failure is a chronic, progressive condition affecting millions of Americans, and despite guideline-directed medical therapy, a substantial share of patients remain symptomatic. That has driven investigational interest in mesenchymal stem cell therapy on the basis of paracrine cardioprotective mechanisms. The most-cited adipose-derived program, the Danish CSCC_ASC trial (NCT03092284), is a useful anchor for understanding the evidence, with one important caveat: it studied an allogeneic product and has completed. What follows is an accurate read of that trial and the broader pipeline, and an honest version of why the long heart-failure time horizon shapes the banking conversation.
- [ALS and Adipose-Derived Stem Cells: The Intrathecal MSC Trial at Mayo Clinic](https://savemyfat.com/als-and-adsc-the-intrathecal-msc-trial-mayo-clinic/): Amyotrophic lateral sclerosis is a fatal, rapidly progressive neurodegenerative disease, and the speed of that progression creates the most time-sensitive banking consideration in regenerative medicine. Most patients lose the functional capacity for an outpatient harvest procedure within roughly 18 to 36 months of diagnosis. Mayo Clinic's Phase 2 trial, NCT03268603, is studying intrathecal autologous adipose-derived mesenchymal stromal cells in ALS. What follows is what neurologists need to know about the trial as registered, the state of the evidence, and the disease-stage timing that makes the banking conversation, if it happens at all, an early-diagnosis conversation.
- [Crohn’s Disease and Adipose-Derived Stem Cells: What the Darvadstrocel Story Tells GI Physicians](https://savemyfat.com/crohns-disease-and-adscs-darvadstrocel-story-for-gi/): Darvadstrocel (cx601, marketed as Alofisel) was the first allogeneic adipose-derived mesenchymal stem cell therapy to receive central marketing authorization from a major regulator, when the European Commission approved it in 2018 for complex perianal fistulas in Crohn's disease. It is also a cautionary case: the confirmatory Phase 3 trial failed in 2023, and the EU marketing authorization was withdrawn at the company's request in December 2024. For GI physicians, the full arc, approval on one pivotal trial, then failure to confirm and withdrawal, is more instructive than the approval alone, and it is the version that survives contact with the current record.
- [Hope Biosciences and the TBI Trial: Autologous Adipose MSCs for Chronic Brain Injury (NCT05951777)](https://savemyfat.com/hope-bio-tbi-trial-adipose-mscs-chronic-brain-injury/): Chronic traumatic brain injury has no FDA-approved disease-modifying or regenerative therapy, leaving treatment largely supportive and rehabilitative. Hope Biosciences' Phase 2 trial, NCT05951777, is studying the company's autologous adipose-derived mesenchymal stem cells in chronic TBI against a saline placebo. The banking question this raises is different from the one in a rapidly progressive disease: many TBI patients are young and otherwise healthy, and the practical timing of a banking conversation tends to fall in the post-injury stabilization window. What follows is what treating physicians need to know about the trial as registered and how the timing consideration fits long-term care planning.
- [The Mayo Clinic Multiple System Atrophy Trial: What Physicians Need to Know (NCT05167721)](https://savemyfat.com/mayo-multiple-system-atrophy-trial-nct05167721/): Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease with no disease-modifying treatment, which makes the question of preserving future options unusually pressing for the patients and physicians who face it. Mayo Clinic's Phase 2 trial, NCT05167721, is studying autologous adipose-derived mesenchymal stem cells administered intrathecally in MSA. What follows is what treating physicians need to know about the trial as registered, the state of the evidence, and the clinical-timing consideration that banking raises in a disease that narrows the window for tissue harvest as it progresses.
- [Active Clinical Trials Using Adipose-Derived MSCs: A 2026 Physician Reference](https://savemyfat.com/active-clinical-trials-in-adipose-derived-mscs-2026/): The clinical case for banking autologous adipose tissue rests on a research pipeline, and that pipeline is best understood from primary sources rather than summaries. As of 2026, active trials are studying adipose-derived mesenchymal stem cells across several condition categories, from neurodegenerative disease to musculoskeletal and inflammatory conditions. What follows is a physician reference to the active programs, with NCT numbers, phases, sponsors, and current status drawn from ClinicalTrials.gov, framed so that the banking connection stays a matter of optionality rather than a promise of access.
- [Adipose Banking and the Orthopedic Physician: Harvest Documentation, Consent, and the SB 1768 Scope](https://savemyfat.com/adipose-banking-for-orthopedic-physicians-rules/): Florida SB 1768 names orthopedic conditions as one of only three categories within its authorized scope for non-FDA-approved stem cell therapy, alongside wound care and pain management. That places orthopedic surgeons and sports medicine physicians in Florida closer to the center of the state's framework than any other specialty. For a physician already harvesting adipose tissue during procedures, that proximity raises a concrete operational question: what has to be documented, from harvest through storage, to keep a banking program compliant and to keep a patient's future options open. What follows addresses harvest documentation, the split between banking consent and therapeutic-use consent, and the orthopedic trial pipeline that gives banking its forward-looking rationale.
- [FDA Warning Letters in Regenerative Medicine: The Pattern Physicians Must Recognize](https://savemyfat.com/fda-warning-letters-in-regenerative-medicine/): The FDA has issued warning letters to stem cell and HCT/P providers for years, and the violations cited fall into a recognizable pattern, almost all of them rooted in 21 CFR Part 1271. Reading that pattern is more useful to a physician than memorizing any single letter, because it shows precisely what the agency looks for. The letters are public record, searchable by anyone, including patients, attorneys, payers, and state medical boards. What follows is the recurring violation set drawn from the FDA's public warning-letter record and a self-audit a physician can run against it.
- [The FTC Stem Cell Enforcement Pattern: What the Stem Cell Institute of America Case Means for Every Provider](https://savemyfat.com/ftc-stem-cell-enforcement-pattern-what-it-means/): In January 2025, federal court orders permanently banned the co-founders of the Stem Cell Institute of America from marketing regenerative medicine treatments and imposed more than $5.1 million in penalties and consumer refunds. The action was brought jointly by the Federal Trade Commission and the Georgia Attorney General. For any physician who markets stem cell or regenerative medicine services, the case is a clear statement of the standard the FTC applies to health claims, and the conduct it treats as a violation. What follows is a factual account of the action and the compliance lessons a provider can take from it.
- [Homologous Use: The Other 361 Criterion Physicians Cannot Ignore](https://savemyfat.com/homologous-use-361-criterion-physicans-cant-ignore/): Minimal manipulation gets most of the attention, but homologous use is the criterion that catches physicians off guard most often. A physician can use a properly processed, genuinely minimally manipulated tissue product and still convert it into a 351 biologic, requiring an IND, simply by using it for a purpose outside the tissue's basic function. The FDA has issued numerous warning letters on exactly this point in the adipose and stem cell space. This is the direct companion to the discussion of minimal manipulation, and it covers what homologous use means, how the FDA applies it to adipose tissue, and the due diligence a physician owes before any use.
- [What “Minimally Manipulated” Really Means Under 21 CFR 1271](https://savemyfat.com/what-minimally-manipulated-really-means-under-1271/): Whether a tissue product is regulated as a 361 HCT/P, needing no pre-market approval, or as a 351 biologic, needing an IND and a BLA, turns on four cumulative criteria under 21 CFR 1271.10. "Minimally manipulated" is the first of those criteria and the most frequently litigated. Getting it wrong, or relying on a supplier who classified a product incorrectly, exposes a physician to FDA enforcement, including warning letters, injunctions, and in serious cases criminal referral. What follows is what minimal manipulation means, how the FDA has defined it, and what it specifically means for adipose tissue.
- [Informed Consent for Stem Cell Banking: What Physicians Must Document Across States](https://savemyfat.com/informed-consent-requirements-for-stem-cell-banking/): Informed consent has always been an ethical and legal baseline in medicine. In non-FDA-approved stem cell therapy, it is now also a specific statutory compliance requirement, and the elements differ by state. Florida SB 1768, Utah's amended Section 58-1-512, and Wyoming SF 48 each condition lawful practice on a written consent that contains particular elements, which means a form that satisfies general medical ethics can still violate a state statute by omitting one required line. What follows compiles the consent requirements across the three active states so a physician can build a form that holds up in each.
- [Current Good Tissue Practice (CGTP): The FDA Standard Your Lab Partner Must Meet](https://savemyfat.com/current-good-tissue-practice-cgpt-fda-standard-lab/): If a physician banks or processes a patient's adipose tissue through a third-party lab, the quality of that tissue is governed by a federal standard called Current Good Tissue Practice. CGTP lives in Subpart D of 21 CFR Part 1271 and applies to every registered HCT/P establishment, including those making 361 products that need no pre-market approval. The physician who uses the tissue is not insulated from that lab's failures. What follows is what CGTP requires and a concrete way for a physician to evaluate whether a lab partner actually meets it.
- [FDA Establishment Registration for HCT/P Providers: What It Is and Why It Is Not Optional](https://savemyfat.com/fda-establishment-registration-for-hct-p-providers/): A common assumption among physicians entering regenerative medicine is that 361 HCT/Ps carry no FDA obligations because they require no pre-market approval. That is wrong, and the misunderstanding can be expensive. 21 CFR Part 1271 imposes registration, listing, and Current Good Tissue Practice requirements on every establishment that manufactures HCT/Ps, including those that qualify under Section 361. Florida's SB 1768 leans directly on this when it requires that stem cells be manufactured in a facility "registered and regulated by FDA." What that registration is, what it does not mean, and what the physician using a registered facility still has to do are covered below.
- [The Multi-State Stem Cell Law Map: Where Your State Stands in June 2026](https://savemyfat.com/multi-state-stem-cell-law-map-where-your-state-stand/): Until 2017, no U.S. state had a law specifically addressing non-FDA-approved stem cell therapy at the provider level. Since California broke that ground, the count has grown to at least half a dozen states with disclosure or authorization frameworks, and the pace is accelerating: Florida, Utah, and Wyoming all enacted or expanded frameworks across 2025 and 2026, with Wyoming's law taking effect July 1, 2026. What follows is a reference map for physicians placing their own state, and their patients' states, on that landscape as of June 2026.
- [Nevada’s Approach to Unapproved Biological Therapies: What Providers Need to Know](https://savemyfat.com/nevadas-approach-to-unapproved-biological-therapies/): Nevada has no stem-cell-specific disclosure or consent statute. Its nonembryonic-cell provisions, NRS 629.300 to 629.390 (enacted 2009), permit the banking, compounding, and administration of nonembryonic cells without imposing a stem-cell-specific notice or consent duty. In 2023, SB 283 amended Nevada's Right to Try law (NRS 454.690) to cover "individualized investigational treatments" based on a patient's genetic profile; it is not a stem cell statute. A 2025 bill that would have required certain providers to discuss stem cell storage and donation options, SB 128, was vetoed on June 10, 2025. Details should be confirmed against the Nevada Revised Statutes and with qualified Nevada counsel.
- [California’s Stem Cell Disclosure Law: What Providers Operating in CA Must Post, Say, and Document](https://savemyfat.com/california-stem-cell-disclosure-law-what-providers/): California was the first state in the country to require physicians to disclose the FDA status of stem cell therapy. SB 512, signed in 2017, added Section 684 to the Business and Professions Code and obligates any licensed practitioner who performs a non-FDA-approved stem cell therapy to post a notice, display it at the entrance, and hand a written copy to the patient before the first treatment. Two newer laws effective January 1, 2026, AB 1415 and SB 351, do not address stem cells specifically but reshape how any California practice, including a regenerative one, can be owned and managed. This post covers all three.
- [IRB Approval vs. Investigational Status: Wyoming SF 48’s Two Pathways for Stem Cell Therapy](https://savemyfat.com/irb-approval-vs-investigational-status-sf-48/): Wyoming's Stem Cell Freedom Act, SF 48, lets a physician perform non-FDA-approved stem cell therapy only if, among other conditions, the therapy is conducted under a current Institutional Review Board approval or the stem cells qualify as an investigational drug, biological product, or device. Those are two distinct legal pathways, and the Act defines each in a specific way. This post is the operational follow-on to the SF 48 overview: it explains what each pathway requires, how long each takes, and which is realistic for which kind of practice.
- [The Wyoming Stem Cell Freedom Act Takes Effect July 1, 2026: What Physicians Need to Know Now](https://savemyfat.com/wyoming-stem-cell-freedom-act-july-1-2026-physicians/): Wyoming's Stem Cell Freedom Act, Senate File 48, was passed during the 2026 budget session and signed into law. It creates a new article of the Wyoming statutes, W.S. 35-4-1101 through 35-4-1106, and it takes effect July 1, 2026. The Act authorizes physicians to recommend and perform certain non-FDA-approved stem cell therapies and shields a compliant physician's license from state disciplinary action. With the effective date close, any Wyoming physician considering this pathway has a narrow window to get the prerequisites in place. This post lays out what the Act actually says.
- [Utah’s Stem Cell Disclosure Law: What Suppliers and Providers Both Must Do Under SB 55](https://savemyfat.com/utah-stem-cell-disclosure-law-suppliers-and-provider/): Utah's stem cell disclosure law lives in Section 58-1-512 of the Utah Code. It began as SB 199 in 2024, which required providers to give patients a written notice and obtain consent before performing non-FDA-approved stem cell therapy. SB 55, passed in the 2026 session and effective May 6, 2026, amended that section (a 2025 bill with the same title, SB 55, passed the Senate but died in the House on March 7, 2025) to add a new obligation aimed upstream at suppliers: persons who supply human cells, tissues, or cellular or tissue-based products for use in stem cell therapy now carry a notice requirement of their own. This post covers what Utah providers and the suppliers who serve them must each do.
- [What Florida’s SB 1768 Means for Advertising Your Stem Cell Practice](https://savemyfat.com/what-florida-sb-1768-means-for-advertising-stem-cell/): Florida's CS/CS/SB 1768 does not just regulate how physicians perform non-FDA-approved stem cell therapy. It regulates how they advertise it. The statute requires a specific notice in every advertisement, and that requirement sits on top of, not instead of, the Federal Trade Commission's rules on health claims and testimonials and the advertising policies of Google and Meta. This post breaks down what a Florida physician must include in stem cell advertising and how the state, federal, and platform layers interact.
- [Florida SB 1768: The Complete Physician Compliance Checklist for Stem Cell Therapy](https://savemyfat.com/florida-sb-1768-the-complete-physician-checklist/): Florida's CS/CS/SB 1768, codified at Sections 458.3245 and 459.0127 of the Florida Statutes and enacted as Chapter 2025-185, took effect July 1, 2025. It authorizes licensed Florida physicians to perform certain stem cell therapies that are not approved by the U.S. Food and Drug Administration, but only inside a narrow set of conditions that govern scope, sourcing facilities, consent, advertising, and sourcing contracts. This checklist walks a Florida MD or DO through every category the statute imposes so that a practice can audit itself before offering any service that falls under the law.
- [Adipose Tissue Banking: 50 Questions Patients Actually Ask, Answered](https://savemyfat.com/adipose-tissue-banking-top-50-questions-answered/): This page answers the 50 questions patients, physicians, and families most commonly ask about adipose tissue banking, the MFAT procedure, expanded access programs, and the ADSC clinical pipeline, organized by topic so you can go directly to what matters most. Each answer is concise and links to the full post on that topic where you need more depth. If your question is not here, use the site search or contact Save My Fat directly.
- [The Adipose-Derived Stem Cell Market in 2026: Science, Pipeline, and What It Means for Patients Who Bank Today](https://savemyfat.com/adipose-derived-stem-cell-market-in-2026/): The adipose-derived stem cell market is one of the most active segments in regenerative medicine in 2026, driven by over four hundred active clinical trials, the December 2024 FDA approval of the first MSC-based biologic, and a growing body of published research documenting the multipotent and immunomodulatory properties of ADSCs across orthopedic, autoimmune, neurological, and aesthetic applications. Understanding where the market is and where the science is headed matters for patients who are considering banking, physicians who are evaluating the program, and anyone trying to separate the legitimate ADSC pipeline from the noise of unregulated clinic marketing. This post covers the science, the market data, the clinical trial pipeline, and the specific implications for patients who bank their cells today.
- [Is Adipose Tissue Banking Worth the Cost? A Transparent Framework for Evaluating the Investment](https://savemyfat.com/is-adipose-tissue-banking-with-the-cost/): Adipose tissue banking costs between $8,000 and $15,000 for the initial package plus annual storage fees, which makes it a significant cash-pay health investment with a return that depends on a pipeline that is maturing but not yet fully realized. Whether it is worth it depends on three things that are entirely specific to you: your financial situation, your health profile and its relevance to the ADSC pipeline, and your comfort with paying for preservation value rather than immediate benefit. This post gives you an honest, structured framework for working through all three, including the things that make banking clearly worth it, the things that make it genuinely uncertain, and the framing that distinguishes a good financial decision from a poor one in this specific category.
- [Why Physicians Are Joining the Save My Fat Provider Network: The Case for Adding Banking to Your Practice](https://savemyfat.com/why-physicians-are-joining-smf-provider-network/): Adipose tissue banking is a service that a growing number of physicians across plastic surgery, aesthetic medicine, orthopedics, and functional medicine are adding to their practices. Not as a departure from their clinical focus, but as a natural extension of it. The harvest technique is within existing physician skill sets, the regulatory framework is established and compliant, and the patient population most interested in banking is the same health-forward, cash-pay demographic that high-quality medical practices already serve. This post covers the clinical case, the practice workflow, the regulatory compliance framework, and what joining the Save My Fat provider network involves.
- [What Happens After You Bank: A Guide to Managing Your Stored Cells and Staying Connected to the Pipeline](https://savemyfat.com/what-happens-after-banking-a-guide-to-managing-cells/): Once your viability certificate arrives and your cells are in cryostorage, the active phase of banking is complete, but the value of what you have preserved is just beginning to develop as the ADSC clinical trial pipeline matures toward approvals. The post-banking relationship involves three ongoing responsibilities: maintaining your storage account, staying informed about pipeline developments relevant to your health profile, and knowing the steps to access your cells when the time comes. This guide covers all three, plus what to do if your health situation changes after banking.
- [Banking Together: Why Couples and Families Are Making Adipose Tissue Banking a Shared Health Decision](https://savemyfat.com/banking-together-as-couples-and-families/): Adipose tissue banking is an individual biological preservation decision, but more health-forward couples and families are approaching it as a shared health investment. Coordinating appointments, planning the cost across household budgets, and making sure that both partners or multiple family members preserve their cells while biological quality is still at its best. The biology of banking is the same for each individual, but the shared decision dynamic changes the conversation. Coordinated banking is more logistically efficient, may offer cost advantages depending on provider programs, and ensures that neither partner delays while waiting for the other to decide. This post covers the practical and biological case for coordinated family banking, how to plan it, and what each person needs to know individually.
- [How to Choose the Right Adipose Tissue Banking Provider: A Patient’s Evaluation Guide](https://savemyfat.com/choose-the-right-adipose-tissue-banking-provider/): Choosing an adipose tissue banking provider is a decision that deserves the same diligence you would apply to any significant cash-pay health investment, because the regulatory compliance of the laboratory, the training of the provider performing the harvest, and the transparency of the banking program all directly affect what you actually get for your investment. The adipose tissue banking space includes both fully compliant, FDA-registered services and a range of offerings that blur the line between banking and unregulated treatment claims, which makes the evaluation framework especially important. This guide gives you seven specific criteria to apply when evaluating any banking service, the questions to ask before you commit, and the red flags that should stop a conversation immediately.
- [What to Expect on Your Adipose Tissue Banking Day: A Step-by-Step Patient Guide](https://savemyfat.com/what-to-expect-on-your-adipose-tissue-banking-day/): The banking harvest is a thirty-minute outpatient procedure performed under local anesthesia at a Save My Fat partner provider's office. No hospital, no general anesthesia, and most patients return to normal activity the same day or the following day. Knowing exactly what to expect before you arrive makes the experience more comfortable and helps you prepare practically for the appointment, the recovery, and the weeks that follow while your cells are being processed. This guide walks through the full banking day from pre-appointment preparation through receiving your viability certificate.
- [Who Should Bank Their Fat Stem Cells? The Ideal Patient Profile for Adipose Tissue Banking](https://savemyfat.com/who-should-bank-their-fat-stem-cells-ideal-patients/): Adipose tissue banking is most valuable for adults who are healthy enough to have the harvest procedure, motivated by a proactive approach to their long-term health, and in a life stage where preserving high-quality cells now gives them meaningful preservation value against the ADSC clinical trial and approval pipeline. It is not a service that is equally valuable for everyone, and an honest assessment of who benefits most helps the right patients make a confident decision while helping others understand whether their specific situation warrants a deeper conversation before proceeding. This post walks through the ideal candidate profile, the factors that strengthen the case for banking, the situations that require physician input first, and the situations where banking may not be the right next step.
- [What Is Save My Fat? The Complete Guide to How the Program Works](https://savemyfat.com/what-is-save-my-fat-the-complete-guide/): Save My Fat is a tissue banking program that allows adults to preserve their own adipose-derived stem cells through a thirty-minute outpatient harvest procedure, processed and cryopreserved by a U.S.-based tissue bank for long-term storage and potential future use in clinical trials, expanded access programs, and FDA-approved therapies as they develop. The program connects patients with trained partner providers across the United States, operates under the FDA Section 361 HCT/P regulatory framework, and gives each patient a viability certificate documenting exactly what was banked and its biological quality. This post explains everything you need to know about how Save My Fat works, who it is for, what the process looks like, and how to get started.
- [How to Talk to Your Doctor About Adipose Tissue Banking: A Patient’s Conversation Guide](https://savemyfat.com/how-to-talk-to-doctor-about-adipose-tissue-banking/): Most patients who are interested in adipose tissue banking will want to discuss it with their primary care physician, specialist, or functional medicine provider before booking, and many will encounter a physician who is not yet familiar with the banking framework, the regulatory structure, or the current state of the ADSC clinical trial pipeline. This post gives you the language, the facts, and the framework to have that conversation clearly and confidently, including how to address common physician concerns about stem cell therapies in a way that distinguishes banking from the unregulated clinic sector. The goal is not to convince your doctor to prescribe banking. It is to have an informed, accurate conversation so you can make the best decision for your own health.
- [How to Think About the Cost of Adipose Tissue Banking: A Framework for Making the Decision](https://savemyfat.com/how-to-think-about-the-cost-adipose-tissue-banking/): Adipose tissue banking is a cash-pay health service typically priced between $8,000 and $15,000 depending on the package, provider, and storage terms, which makes it a significant financial decision that deserves a clear-eyed evaluation framework rather than an impulse. The right way to think about banking cost is not as a medical procedure expense but as an option-value investment: you are paying to preserve a biological asset at its current quality against a pipeline of therapies that is growing and maturing. This post gives you the full cost picture, what is included, what ongoing costs look like, how banking compares to other health investments at similar price points, and how to evaluate whether the cost makes sense for your specific situation.
- [Adipose Tissue Banking and Longevity Medicine: Why Health-Forward Adults Are Banking Their Fat Stem Cells Now](https://savemyfat.com/adipose-tissue-banking-and-longevity-medicine/): The longevity medicine movement has given health-forward adults a framework for thinking about their biology as something to measure, optimize, and preserve, not just treat when something goes wrong. Adipose tissue banking fits directly into that framework: it is a one-time procedure that preserves your own adipose-derived stem cells at their current biological quality, for potential future use in a pipeline of therapies and trials that is growing faster than most patients realize. The science is credible, the regulatory framework is established, and the window for banking at peak cell quality does not stay open indefinitely. This post explains why banking is the logical next step for anyone already engaged in longevity medicine practices.
- [Adipose-Derived Stem Cells in Neurological Conditions: What the Research Shows](https://savemyfat.com/adipose-derived-stem-cells-neurological-conditions/): Neurological conditions, including ALS, stroke recovery, spinal cord injury, Parkinson's disease, and multiple sclerosis, represent one of the most active areas of mesenchymal stem cell research, driven by the lack of effective standard treatments for most of these conditions and the biological plausibility of MSC neuroprotective and anti-inflammatory mechanisms. The evidence base for adipose-derived stem cell neurological applications is earlier-stage than orthopedics or aesthetics. Most published data is from Phase 1 safety trials and early Phase 2 studies, with larger randomized trials currently recruiting. This post reviews the mechanism, the condition-by-condition evidence, the active trial pipeline, and the expanded access framework for patients who cannot wait for trial completion.
- [Adipose-Derived Stem Cells in Aesthetic Medicine: What Plastic Surgeons and Patients Need to Know](https://savemyfat.com/adipose-derived-stem-cells-in-aesthetic-medicine/): Aesthetic medicine is the most commercially mature application area for adipose-derived stem cells, with a published evidence base covering fat grafting enhancement, skin rejuvenation, scar treatment, and wound healing that stretches back over a decade. The biological mechanism is well-characterized: ADSCs secrete growth factors that promote angiogenesis, collagen synthesis, and tissue regeneration, which makes them a natural complement to aesthetic procedures that depend on tissue quality and vascularization. For plastic surgeons and aesthetic physicians who already perform fat harvesting, banking is the most natural service extension available. Same technique, same tissue, same patient.
- [Adipose-Derived Stem Cells in Autoimmune and Inflammatory Conditions: What the Evidence Shows](https://savemyfat.com/adscs-in-autoimmune-and-inflammatory-conditions/): The December 2024 FDA approval of Ryoncil for steroid-refractory acute graft-versus-host disease was not an orthopedic milestone. It was an immune milestone, confirming that the FDA will approve mesenchymal stem cell-based therapies for immune and inflammatory conditions when the Phase 3 evidence supports them. Adipose-derived stem cells share the same core immunomodulatory properties that drove the Ryoncil approval, and active clinical trials are investigating ADSCs in Crohn's disease, multiple sclerosis, lupus, rheumatoid arthritis, and other inflammatory conditions. This post reviews the biological mechanism, the published evidence, and the active trial pipeline for autoimmune and inflammatory applications of ADSCs, and explains what it means for patients with these conditions who are evaluating banking or trial enrollment.
- [Adipose-Derived Stem Cells in Orthopedics: What the Clinical Evidence Shows in 2026](https://savemyfat.com/adipose-derived-stem-cells-in-orthopedics-in-2026/): Orthopedic applications, particularly knee and hip osteoarthritis, represent the largest and most developed category of adipose-derived stem cell clinical research, with multiple systematic reviews, meta-analyses, and active Phase 2 and Phase 3 trials now in the published literature. Published data from randomized and observational trials have reported significant improvements in pain scores and functional outcomes in patients receiving ADSC-based interventions, though no ADSC-based orthopedic therapy has yet received FDA approval. This post summarizes the clinical evidence base as of 2026, maps the active trial pipeline, and explains what this evidence means for a patient considering banking or a physician evaluating whether to offer banking to orthopedic patients.
- [Expanded Access Programs for Investigational Drugs: What Physicians and Patients Need to Know](https://savemyfat.com/expanded-access-programs-for-investigational-drugs/): Expanded access, also called compassionate use, is the FDA pathway that allows patients with serious or life-threatening conditions to access investigational drugs, biologics, or medical devices outside of a clinical trial when no comparable alternative therapy is available. The process requires the treating physician to submit a request to the FDA and obtain agreement from the drug or biologic sponsor, but it is a formal, documented, FDA-recognized pathway, not a workaround. For patients researching whether banking their own stem cells could support an expanded access application, and for physicians who want to understand how to navigate this process for a qualifying patient, this post explains the full framework.
- [MFAT Injections: What They Are, What the Evidence Shows, and How They Relate to Banking](https://savemyfat.com/mfat-injections-what-they-are-what-evidence-shows/): MFAT, micro-fragmented adipose tissue, is a preparation of mechanically processed fat tissue that retains an intact stromal vascular niche, including adipose-derived stem cells, pericytes, and extracellular matrix components, and is injected at the site of injury or disease. Multiple clinical trials have evaluated MFAT injections for orthopedic applications, particularly knee osteoarthritis, with published data demonstrating improvements in pain and functional outcomes. MFAT is not FDA-approved as a treatment for any condition. It is an investigational approach being studied in clinical trials. This post explains what MFAT is, what the current evidence shows, how it differs from banking, and what a patient or physician considering MFAT should know about the regulatory context.
- [How Your Patients’ Cells Are Processed and Stored: What Providers Need to Know](https://savemyfat.com/how-patient-cells-are-processed-and-stored/): After the harvest, every step involving the patient's tissue happens at the tissue bank's US-based, FDA-registered laboratory. The tissue bank receives the specimen, isolates and processes the adipose-derived stem cells, performs viability testing, cryopreserves the cells into a documented vial inventory, and manages long-term liquid nitrogen storage under current Good Tissue Practice regulations. The provider's role ends with the packaged specimen. the tissue bank's role covers everything that determines the quality and integrity of what the patient has banked.
- [What Training Do Providers Need Before Performing Adipose Tissue Banking?](https://savemyfat.com/what-training-do-providers-need-for-adipose-banking/): Save My Fat provides comprehensive onboarding to every partner provider before they see their first banking patient, covering the harvest procedure, patient consultation framework, informed consent requirements, chain-of-custody documentation, and specimen shipping protocol. Physicians already comfortable with minor liposuction techniques will find the procedural training familiar. Those who are not will find it achievable. No external certification is required beyond Save My Fat's onboarding program to begin offering banking in the practice.
- [The Harvest Procedure Step by Step: What Providers Actually Do](https://savemyfat.com/the-harvest-procedure-step-by-step-for-providers/): The adipose tissue harvest is a 30-minute outpatient procedure performed under local anesthesia: approximately 20 cc of subcutaneous fat collected via a small-bore cannula, packaged under chain-of-custody protocols, and shipped to a U.S.-based tissue bank for processing. For physicians already comfortable with minor liposuction techniques, the procedure requires minimal additional learning. For those who are not, Save My Fat's training program covers every step before the first patient is scheduled. This guide walks through the full procedure from the provider's perspective, including patient selection, the harvest technique, specimen handling, documentation, and adverse event reporting obligations.
- [How to Introduce Stem Cell Banking to Patients Without Overstepping Compliance Lines](https://savemyfat.com/how-to-introduce-stem-cell-banking-to-patients/): The most common reason physicians hesitate before introducing stem cell banking to patients is not skepticism about the science. It is uncertainty about what they are allowed to say. The distinction between permissible and impermissible language in this space is precise, and getting it wrong carries real professional and regulatory risk. This guide provides a clear compliance framework: what physicians can say, what they cannot say, why the distinction matters, and a model patient conversation that demonstrates how to introduce banking accurately and professionally.
- [The First FDA-Approved Mesenchymal Stem Cell Product: What It Means for Regenerative Medicine Providers](https://savemyfat.com/the-first-fda-approved-mesenchymal-stem-cell-product/): In December 2024, the FDA approved Ryoncil (remestemcel-L-rknd), making it the first mesenchymal stem cell product to complete the full FDA approval pathway. For physicians evaluating whether the stem cell field is scientifically and regulatorily credible, this approval is the clearest available answer. It does not mean that adipose-derived cell therapies are currently approved for any condition. It does mean the FDA has now demonstrated it will approve MSC-based products when the clinical evidence supports it.
- [What Your Patients Already Believe About Stem Cell Banking (And What That Means for Your Practice)](https://savemyfat.com/what-your-patients-believe-about-stem-cell-banking/): Patients asking about stem cell banking have usually done research before they ask. They have read wellness blogs, watched YouTube videos, seen clinic ads, and arrived with a mix of accurate science, reasonable conclusions, and significant misconceptions all blended together. A physician who understands what patients actually believe, and where those beliefs came from, can engage the conversation with precision instead of starting from scratch or dismissing the question entirely.
- [How Stem Cell Banking Fits Into a Cash-Pay Practice Model in 2026](https://savemyfat.com/how-stem-cell-banking-fits-in-cash-pay-practice/): For physicians already working in a cash-pay or hybrid model, stem cell banking adds a compliant service line that requires no insurance billing, no new equipment, and no additional laboratory infrastructure. The harvest is a 30-minute outpatient procedure under local anesthesia. A U.S.-based tissue bank handles all cell processing and storage. Save My Fat routes patients in the provider's area directly to the practice. The revenue model is front-loaded on the banking package and recurring on every future vial use, creating a compounding patient relationship from a single procedure.
- [The Regenerative Medicine Market in 2026: What Physicians Need to Know Before Deciding](https://savemyfat.com/regenerative-medicine-market-in-2026-for-physicians/): Regenerative medicine is no longer a fringe category. The adipose-derived stem cell market is growing at a documented 15% annually, the FDA approved its first mesenchymal stem cell product at the end of 2024, and more than 400 clinical trials involving adipose-derived cells are actively recruiting worldwide. For physicians considering whether to add stem cell banking to their practice, understanding the market trajectory and scientific pipeline is the difference between leading the curve and following it.
- [What Is Adipose Tissue Banking and Why Are Physicians Adding It to Their Practices?](https://savemyfat.com/what-is-adipose-banking-and-why-physicians-add-it/): Adipose tissue banking is a compliant, cash-pay service that allows patients to preserve their own fat-derived stem cells today for potential future use in FDA-regulated pathways. For physicians, it represents a turnkey addition to an existing practice: a 30-minute harvest procedure, a fully managed lab partnership, and a patient referral model that brings qualified patients directly to the provider. This guide covers the complete model, what banking is, how the service is structured, what the regulatory framework requires, and what physicians need to know before deciding whether it belongs in their practice.
- [Why Patients Are Asking Their Doctors About Stem Cell Banking Right Now](https://savemyfat.com/why-patients-are-asking-doctors-stem-cell-banking/): Patients across specialties, including orthopedics, aesthetics, functional medicine, and primary care, are arriving with specific questions about adipose-derived stem cell banking that most physicians were not trained to answer. The underlying demand is not a social media blip. It is being driven by a documented inflection point in regenerative medicine: the FDA's first approval of a mesenchymal stem cell product in December 2024, an adipose-derived stem cell market that independent research firms project to grow at double-digit annual rates through 2033, and more than 450 clinical trials registered on ClinicalTrials.gov, roughly 80 to 150 of them currently active. Understanding what your patients have already read, and why, is the first step toward deciding whether tissue banking belongs in your service mix.
- [Your Fat as an Endocrine Organ: Adipokines, Organs, and Where ADSCs Fit In](https://savemyfat.com/your-fat-as-an-endocrine-organ-where-adscs-fit-in/): Adipose tissue is more than stored energy. It is an active endocrine organ that releases hormones and signaling molecules into the bloodstream and communicates continuously with the brain, liver, muscle, pancreas, heart, and immune system. When adipose tissue is healthy and well-regulated, this signaling helps keep appetite, insulin sensitivity, inflammation, and vascular tone in balance. When it becomes dysfunctional, as happens in obesity and metabolic stress, the same signaling machinery can drive insulin resistance, chronic inflammation, and a cluster of conditions now described as adiposity-based chronic disease.
- [Nerves, Pain, and Your Fat: How Adipose Tissue, Innervation, and ADSCs Connect to Chronic Pain](https://savemyfat.com/nerves-pain-and-your-fat-how-adipose-and-adsc-help/): Fat tissue is wired with nerves and connected to pain in more ways than most people realize. Adipose tissue receives signals from the brain through sympathetic nerves that regulate metabolism and temperature, and it sends information back through sensory nerves that report on tissue conditions to the spinal cord and brain. Obesity and visceral fat have both been linked to higher rates of chronic pain, and the mechanisms connecting them include inflammation, neuro-immune crosstalk, and changes in nerve function. Adipose-derived stem cells are also being studied as tools to support injured nerves in preclinical research, with early human work beginning in specific neurological conditions.
- [Your Fat as an Immune Organ: How Adipose Tissue and ADSCs Talk to the Immune System](https://savemyfat.com/how-adipose-tissue-and-adscs-talk-to-immune-system/): Fat is not just a storage depot. Adipose tissue contains immune cells, produces hormones and signaling molecules called adipokines, and is in constant conversation with the immune system across the entire body. When adipose tissue is healthy, this active role helps maintain metabolic balance and immune homeostasis. When it becomes inflamed, as happens in obesity and metabolic disease, it can drive a chronic low-grade inflammatory state that interferes with insulin signaling and contributes to a range of systemic conditions. Understanding this changes what it means to think about your fat.
- [Hype, Hope, and the Placebo Effect in Adipose-Derived Stem Cell and Regenerative Therapies](https://savemyfat.com/hype-hope-and-the-placebo-effect-in-adipose/): Regenerative medicine occupies a space where genuine scientific progress and overblown marketing coexist so closely that patients can rarely tell them apart from the outside. Testimonials from people who paid thousands of dollars for a stem cell injection and felt dramatically better for months are real accounts of real experiences. But most patients never hear about the control groups, the placebo effects, or the large trials where orthobiologics performed no better than corticosteroid at one year. This article explains how expectations, trial design, and the biology of placebo responses shape what we think regenerative therapies can do, and what patients can do with that understanding when making decisions about their own care.
- [How Adipose Tissue Biobanks Actually Work: Governance, Access, and Patient Protections](https://savemyfat.com/how-adipose-tissue-biobanks-actually-work/): When people hear the word "biobank," they usually picture a freezer full of labeled vials. The freezer is real, but it is the least interesting part of what a biobank actually is. The real work is in the rules: who decides what gets stored, who can take samples out, what research proposals are acceptable, and how donors are protected when they hand over biological material that may be used in ways they cannot fully anticipate. Adipose tissue biobanks for research and personal-use services for future clinical options both have to answer these questions. The standards that research biobanks have developed over decades offer a useful framework for evaluating any offer to store your tissue.
- [Ethics, Ownership, and Law in Adipose Tissue Banking and Stem Cell Therapy: What Patients Need to Know](https://savemyfat.com/ethics-ownership-law-adipose-tissue-stem-cells/): Banking fat and using adipose-derived products sit at a crossroads of biology, law, and ethics that most marketing materials do not explain. Patients are not just storing tissue when they sign a banking agreement. They are entering a legal relationship that defines who owns the stored material, what it can be used for, whether commercial products can be developed from it, and what rights they retain if things change. Regulators, professional medical ethics codes, and state legislatures have all started paying closer attention to this landscape, and patients have more at stake in understanding it than they are usually told.
- [Extracellular Vesicles, Exosomes, and Adipose-Derived Cells: How MISEV Guidelines Shape Safe Regenerative Medicine](https://savemyfat.com/extracellular-vesicles-exosomes-adscs/): Extracellular vesicles are tiny membrane-enclosed particles released by virtually every cell type in the human body. They carry proteins, lipids, and nucleic acids from the cells that produce them, and they influence the behavior of cells they encounter. In the last decade, these particles have become one of the most studied topics in cell biology, and they are now central to discussions about the future of regenerative medicine. Many clinics have adopted the word "exosomes" as a marketing shorthand for something loosely defined as healing particles from stem cells. The International Society for Extracellular Vesicles has responded by developing rigorous guidelines for how these particles should be defined, isolated, characterized, and studied in ways that protect scientific integrity and patient safety.
- [Adipose-Derived Stem Cells in Kidney, Heart, and Lung Disease: What Organ Trials Are Actually Showing](https://savemyfat.com/adipose-derived-stem-cells-in-kidney-heart-lung/): Adipose-derived stem cells and their secreted factors are being studied across multiple organ systems because they appear to modulate inflammation, reduce scarring, and support cell survival in animal models of chronic organ disease. Patients with kidney, heart, or lung conditions now encounter headlines about fat stem cell trials and case reports and want to understand what those studies have actually measured. This article walks through the organ-by-organ evidence, what the early human data show, and what they do not yet support in clinical practice.
- [Adipose-Derived Stem Cells, Aging, and “Inflammaging”: What the Research Actually Shows](https://savemyfat.com/adipose-derived-stem-cells-aging-and-inflammaging/): Adipose tissue and its resident stem cells do not stay the same over a lifetime. They feel the effects of aging, weight gain, and chronic low-grade inflammation in measurable ways that researchers have been documenting for more than a decade. The term "inflammaging" captures a phenomenon increasingly recognized as central to age-related decline: a persistent, low-intensity inflammatory state that rises with age and that adipose tissue actively contributes to. Researchers are now asking whether using younger or healthier adipose-derived cells or their secreted factors could help older tissues function better, and early animal and human data are beginning to map what that might mean.
- [Adipose-Derived Stem Cells in Orthopedics: Cartilage, Tendons, and Osteoarthritis](https://savemyfat.com/adipose-derived-stem-cells-in-orthopedics/): Adipose-derived stem cells are now part of almost every conversation about regenerative orthopedics, appearing in the marketing of pain clinics, in orthopedic surgery journals, and in the vocabulary patients bring to their appointments. Patients hear that fat-derived cells may reduce pain and help cartilage in osteoarthritis and sports injuries, and the claims range from carefully hedged research summaries to aggressive promises of cartilage regeneration and joint replacement avoidance. The science behind these cells is real and genuinely interesting, but the evidence base is still developing, and not all products marketed as "fat stem cell injections" are the same thing under the same regulatory framework.
- [Adipose-Derived Stem Cells in Neurology: Stroke, Spinal Cord Injury, ALS, and Brain Disorders](https://savemyfat.com/adipose-derived-stem-cells-in-neurology/): Adipose-derived stem cells have attracted growing attention in neurology because they secrete growth factors that support damaged tissue, modulate inflammation, and appear to influence recovery in animal models of several serious neurologic conditions. Researchers are now testing whether these properties can translate into clinical benefit in conditions like ischemic stroke, spinal cord injury, ALS, and selected brain disorders. That translation is happening slowly and carefully, in early-phase clinical trials focused primarily on safety and feasibility, and the work remains investigational rather than established standard care.
- [Adipose-Derived Stem Cells in Metabolic and Endocrine Research: Obesity, Insulin Resistance, and Fatty Liver Disease](https://savemyfat.com/adipose-derived-stem-cells-metabolic-and-endocrine/): Adipose tissue is more than stored fat. It is an active endocrine organ that releases hormones, cytokines, and signaling molecules that influence appetite, insulin sensitivity, inflammation, and organ function throughout the body. Adipose-derived stem cells sit at the center of this system, and in obesity and metabolic disease they can act in ways that either worsen or, in some experimental contexts, potentially help correct metabolic dysfunction. Understanding which is which, and under what conditions, is where the current research stands.
- [Adipose-Derived Stem Cells and the Tumor Microenvironment: What Patients Should Know About Safety and Cancer Risk](https://savemyfat.com/adipose-derived-stem-cells-and-the-tumor-microenviro/): Adipose-derived stem or stromal cells are present in and around many tumors, particularly in organs where fat tissue is abundant, such as the breast. Researchers have spent the last decade studying how these cells interact with cancer, and the findings are more complex and context-dependent than most patients hear. Some laboratory and animal studies suggest pro-tumor effects under certain conditions; others suggest neutral or context-dependent results; and clinical series following fat grafting procedures have not, so far, demonstrated a clear overall increase in cancer recurrence. Patients often encounter simplified versions of this story on both ends of the spectrum, and understanding the full picture requires holding uncertainty in view.
- [How Adipose-Derived Stem Cells Modulate the Immune System (And What That Means for Future Therapies)](https://savemyfat.com/how-adipose-derived-stem-cell-modulate-immune-system/): Adipose-derived stem cells are not just building blocks for new tissue. They also communicate actively with the immune system, releasing signaling molecules and interacting directly with immune cells in ways that researchers are still working to characterize. Scientists are exploring whether this immune modulation could eventually be useful in certain inflammatory and immune-mediated diseases, but most of that work is still in the research phase, ranging from laboratory experiments to early-stage clinical trials. Understanding what the science actually shows, and what it does not yet support, is the point of this guide.
- [Adipose-Derived Stem Cells in Wound Healing Research: A Deeper Look at Published Trials](https://savemyfat.com/adipose-derived-stem-cells-in-wound-healing-research/): Chronic wounds are one of the most persistent and difficult challenges in medicine. Diabetic foot ulcers, pressure ulcers, and ischemic limb wounds affect millions of people and often fail to heal even with best-practice wound care. Researchers are now testing whether adipose-derived stem and stromal cells might support healing in these conditions, and a growing number of human trials have been registered and published. This work is still in the research phase and not standard care, but the published evidence is substantive enough to be worth understanding clearly.
- [Adipose-Derived Stem Cells in Cardiovascular Research: What Trials Are Currently Registered](https://savemyfat.com/adipose-derived-stem-cells-cardiovascular-research/): Researchers are studying whether adipose-derived cells might one day contribute to the treatment of certain cardiovascular conditions, but this work is still in the research phase and no products have been approved. If you have seen headlines about "fat stem cells healing the heart" and wondered whether those stories reflect real science or marketing, this guide is for you. The goal here is to explain what clinical trials are actually registered, what those trials have explored, and what the current state of the evidence does and does not support.
- [What Informed Consent Means in Regenerative Medicine Research](https://savemyfat.com/what-informed-consent-means-in-regenerative-medicine/): Informed consent is a process, not a signature on a form. It is the foundation of ethical research involving human beings, and it exists to ensure that every person who participates in a clinical study does so with a clear understanding of what the study involves, what the risks are, and that their participation is entirely their own choice. In practice, patients are often handed a thick document, given limited time to read it, and asked to sign at the bottom. This article explains what informed consent should actually look like, what regulations require it to include, and how to recognize when the process is being used correctly versus when it is being misused to market unapproved products.
- [What Is 21 CFR Part 1271 and Why It Governs Your Tissue Storage](https://savemyfat.com/what-is-21-cfr-part-1271-and-why-it-governs-tissue/): Twenty-one CFR Part 1271 is the core FDA regulation that establishes safety and quality rules for human cells, tissues, and cellular and tissue-based products, a category that includes banked adipose tissue. The citation looks like legal code, and in a technical sense it is, but its requirements have very real consequences for how tissue is collected, screened, processed, stored, labeled, and eventually used. If you are considering tissue banking, or have already banked your tissue, understanding what this regulation actually requires is one of the most practical things you can do.
- [How to Compare Adipose Tissue Banking Services: A Patient Evaluation Framework](https://savemyfat.com/how-to-compare-adipose-tissue-banking-services/): The adipose tissue banking market has grown substantially in recent years, and the services available today vary widely in their regulatory standing, scientific rigor, and honest communication with patients. This article provides a five-category evaluation framework that any patient can apply to any tissue banking service before committing, regardless of which service they are considering. The framework is designed to cut through marketing language and focus on verifiable facts. It applies equally to every service in this space, including Save My Fat.
- [What Questions Should You Ask Before Banking Your Tissue?](https://savemyfat.com/what-questions-should-you-ask-before-tissue-banking/): Choosing an adipose tissue banking service is a significant financial and medical decision, and not all services operate at the same level of regulatory compliance, scientific rigor, or transparency. This guide provides a practical checklist of the specific questions every patient should ask before committing to any tissue banking service, and explains what a strong, trustworthy answer looks like alongside what should raise concern. These questions apply to any service you are evaluating, including Save My Fat, and a legitimate service should welcome every one of them.
- [What Does “Intact Adipose Tissue” Mean and Why Does It Matter Regulatorily?](https://savemyfat.com/what-does-intact-adipose-tissue-mean/): If you have been researching adipose tissue banking, you have probably come across terms like "intact tissue," "minimal manipulation," and "SVF" used in ways that sound important but are never quite explained. These are not just technical phrases. They describe a regulatory distinction with direct legal consequences under federal law, and the choice a banking service makes about how to process your tissue determines which regulatory pathway applies to that service. This guide explains what intact adipose tissue is, how the FDA classifies different types of adipose processing, and why the difference between intact tissue banking and SVF isolation matters under the law. By the end, you will have the vocabulary and context to ask the right questions before choosing a banking service.
- [What Is Cryopreservation and How Is Tissue Viability Measured After Thawing?](https://savemyfat.com/what-is-cryopreservation-and-how-is-tissue-measured/): One of the most important questions patients ask about adipose tissue banking is whether their tissue will still be biologically useful after years or even decades in storage. That question deserves a serious, science-based answer rather than reassurances without evidence. This guide explains how cryopreservation works at the cellular level, walks through how viability is measured after thawing, and explains precisely what published viability numbers mean and, just as importantly, what they do not mean. By the end, you will have a realistic understanding of what the science supports and what questions to ask any banking facility you consider.
- [What Happens to Your Fat After Banking? Step-by-Step From Collection to Storage](https://savemyfat.com/what-happens-to-your-fat-after-banking-step-by-step/): If you are considering adipose tissue banking, or have already scheduled a procedure, one of the most natural questions you can have is: what actually happens to my tissue after it leaves my body? The answer is a carefully sequenced process governed by federal regulations and informed by decades of cryobiology research. This guide walks through every stage from mini-liposuction collection through long-term cryogenic storage, explaining what happens at each step, why it matters for preserving tissue quality, and what quality controls protect your sample along the way.
- [What Are Mesenchymal Stromal Cells? Why Scientists Are Updating the Terminology](https://savemyfat.com/what-are-mesenchymal-stromal-cells-mscs/): If you have spent any time researching regenerative medicine or adipose tissue banking, you have almost certainly encountered two terms used interchangeably: "mesenchymal stem cells" and "mesenchymal stromal cells." You may have also seen "Medicinal Signaling Cells" thrown into the mix. These terms look similar, are often abbreviated the same way, and can appear in the same sentence in scientific literature, clinical trial listings, and clinic marketing materials alike. The confusion is not your fault. The scientific community has been actively debating and updating this terminology for over two decades, and the reasons behind that debate have real consequences for patients. This article explains where the terms came from, why they were changed, what the current scientific standards are, and how all of it applies to adipose-derived cells specifically.
- [Adipose-Derived Stem Cells in Autoimmune Conditions: What Early Research Is Exploring](https://savemyfat.com/adipose-derived-stem-cells-in-autoimmune-conditions/): If you live with an autoimmune condition or care for someone who does, you have probably come across the phrase "stem cell therapy" at some point, often attached to claims that range from cautiously hopeful to wildly overblown. What is harder to find is a clear, honest account of what researchers are actually studying, what phase that work is in, and what patients should realistically understand before bringing any of it to their physician. This guide fills that gap. It explains the immunobiology behind why scientists are interested in adipose-derived stem cells for immune-related conditions, which specific condition areas have registered clinical trials, and what the current evidence does and does not support.
- [How Clinical Trial Enrollment Works: Inclusion Criteria, Exclusion Criteria, and What Determines Eligibility](https://savemyfat.com/how-clinical-trial-enrollment-works/): If you have found a clinical trial that seems relevant to your situation and are now staring at a list of eligibility requirements you do not fully understand, you are in exactly the right place. The enrollment process for clinical trials has a defined structure, and knowing what each stage involves makes it far less intimidating to navigate. This guide explains what inclusion and exclusion criteria are, why they exist, what the formal screening process looks like from first contact through confirmed enrollment, and how to prepare at each step.
- [What Is the Right to Try Act and How Does It Differ From Expanded Access?](https://savemyfat.com/what-is-the-right-to-try-act-and-how-does-it-differ/): TLDR: The Right to Try Act (2018) and the FDA's Expanded Access Program are both legal pathways for accessing investigational therapies outside clinical trials. The key difference is oversight: Expanded Access involves FDA review and IRB protection; Right to Try does not. Both require manufacturer consent, which is voluntary and cannot be compelled. Understanding the tradeoffs between speed and safeguards is essential before pursuing either pathway.
- [Adipose-Derived Stem Cells in Orthobiologics Research: What Knee, Hip, and Shoulder Trials Have Reported](https://savemyfat.com/adipose-derived-stem-cells-orthobiologics-research/): This article covers the orthobiologics research landscape, specifically what registered clinical trials have reported about adipose-derived stem cells (ADSCs) in knee, hip, and shoulder applications. It explains the outcome measures those trials use, presents the data honestly including its limitations, and gives you the tools to evaluate claims critically rather than rely on marketing.
- [What Is Paracrine Signaling? How ADSCs Communicate Without Becoming New Cells](https://savemyfat.com/what-is-paracrine-signaling/): When researchers discuss why adipose-derived stem cells are scientifically interesting, they often describe something that surprises patients: these cells may not work primarily by differentiating into new tissue. Instead, the current evidence points toward a different mechanism entirely, one built on chemical communication. Understanding that mechanism, called paracrine signaling, gets you much closer to understanding what the science actually says and what researchers are still trying to prove.
- [What ClinicalTrials.gov Phase I, II, and III Actually Mean for Patients](https://savemyfat.com/what-clinical-trials-gov-phase-1-2-3-actually-mean/): You have probably seen the words "Phase 1" or "Phase 3" attached to a clinical trial and wondered what they actually tell you. The labels show up in news headlines, on ClinicalTrials.gov search results, and in marketing materials from clinics with very different motives. Understanding what each phase means, what it does not mean, and how phase status applies to regenerative medicine research can help you read the research landscape more honestly and make better decisions about your own health planning.
- [Adipose-Derived Stem Cells in Atopic Dermatitis and Immune-Related Skin Disease: What the Research Actually Shows](https://savemyfat.com/adipose-stem-cells-in-atopic-dermatitis-and-immune/): Atopic dermatitis affects roughly 30 million Americans and remains one of the most common chronic inflammatory skin conditions in the world. In recent years, FDA-approved biologics like dupilumab and JAK inhibitors have expanded treatment options for moderate-to-severe cases. At the same time, a different conversation has been building online: clinics and social media accounts promoting "stem cell facials," "exosome skin treatments," and "fat-derived stem cell injections" for eczema, psoriasis, and vitiligo.
- [Microfragmented Adipose Tissue (MFAT): How It Works, Where It Is Being Studied, and What Patients Should Watch For](https://savemyfat.com/microfragmented-adipose-tissue-mfat-how-it-works/): TLDR Microfragmented adipose tissue, commonly called MFAT, is a specific way of processing fat tissue that has been studied in randomized clinical trials for knee osteoarthritis, wound healing, and other conditions. Some of those trials show genuinely interesting results. Others show outcomes no better than a saline placebo. None of them has led to FDA approval.
- [Adipose Tissue as an Endocrine Organ: Why Fat Health Matters for Future Regenerative Options](https://savemyfat.com/adipose-tissue-why-fat-health-matters-for-future-use/): For most of the 20th century, scientists treated body fat as biological packing material: a passive depot that stored calories and cushioned organs. That view changed dramatically in 1994 when researchers discovered leptin, a hormone produced almost exclusively by fat cells. That single finding proved that adipose tissue actively communicates with the brain to regulate appetite and energy balance. In the decades since, researchers have identified dozens of additional signaling molecules secreted by fat, and modern science now recognizes adipose tissue as one of the largest endocrine organs in the human body.
- [Adipose-Derived Stem Cells in Hair Restoration and Skin Rejuvenation: What Clinical Studies Actually Show](https://savemyfat.com/adipose-stem-cells-in-hair-and-skin-clinical-trials/): Hair loss affects approximately 50% of men and 40% of women by midlife, and the cosmetic effects of skin aging concern millions more. In recent years, clinics and social media have aggressively promoted "stem cell" and "exosome" treatments for hair regrowth and facial rejuvenation, often with dramatic before-and-after photos and bold promises. The reality is more complicated. Genuine clinical research into adipose-derived cells for hair and skin applications does exist, and some early results are encouraging, but the evidence base remains small, the follow-up periods are short, and no adipose-derived stem cell, stromal vascular fraction (SVF), conditioned media, or exosome product is FDA-approved for hair loss or any dermatologic condition in the United States. This article separates the published clinical data from the marketing hype.
- [Adipose-Derived Stem Cells in Neurological Conditions: What Clinical Trials Are Investigating](https://savemyfat.com/adipose-stem-cells-in-neurological-conditions/): Neurological conditions, including spinal cord injury, traumatic brain injury, stroke, Alzheimer's disease, and multiple sclerosis, represent some of the most challenging areas of modern medicine. The central nervous system has limited capacity for self-repair after injury or disease, and treatment options for many of these conditions remain focused on symptom management rather than restoring lost function. Researchers are investigating whether the immunomodulatory and neuroprotective properties of adipose-derived mesenchymal stem cells (ADSCs) could offer new directions for these conditions. A Phase I clinical trial published in Nature Communications in 2024 by Mayo Clinic investigators reported that intrathecal delivery of autologous adipose-derived MSCs was well-tolerated in patients with traumatic spinal cord injury, with seven of ten participants showing functional improvement (Bydon et al., 2024).
- [Adipose-Derived Stem Cells in Wound Healing and Tissue Repair: What Researchers Are Studying](https://savemyfat.com/adipose-stem-cells-in-wound-healing-and-tissue/): Chronic wounds affect approximately 8.2 million Americans, and diabetic foot ulcers alone are responsible for over 100,000 lower limb amputations each year. Adipose-derived stem cells (ADSCs) and their cell-free derivatives are among the most actively investigated regenerative approaches for wound healing. This guide covers published clinical trial results, 2025 meta-analyses, active trials on ClinicalTrials.gov, emerging exosome research, FDA regulatory context, and what this research means for patients considering adipose tissue banking.
- [Adipose-Derived Stem Cells in Autoimmune and Inflammatory Disease Research: What the Science Shows](https://savemyfat.com/adipose-stem-cells-in-autoimmune-and-inflammatory/): Autoimmune and inflammatory diseases affect millions of Americans, and many patients struggle with treatments that provide incomplete relief or carry significant side effects. Researchers are investigating whether adipose-derived mesenchymal stromal cells (ADSCs) could play a role in addressing these complex conditions. This guide walks through the current clinical evidence, the regulatory lessons learned from the first approved adipose-derived cell product, and what the evolving research landscape means for patients considering adipose tissue banking.
- [Adipose-Derived Stem Cells and Osteoarthritis: What Clinical Trials Are Investigating Right Now](https://savemyfat.com/adipose-derived-stem-cells-and-osteoarthritis-tria/): If you are exploring regenerative medicine options for osteoarthritis, understanding the current state of clinical research is essential before making any decisions. This guide provides a comprehensive, science-based overview of clinical trials studying adipose-derived stem cells for osteoarthritis, including trial phases, safety findings, regulatory context, and what this research landscape means for patients considering adipose tissue banking.
- [How to Spot Fake Stem Cell Clinics: Red Flags, FDA Warnings, and How to Find Legitimate Care](https://savemyfat.com/how-to-spot-fake-stem-cell-clinics-red-flag-fda/): TL;DR Unregulated stem cell clinics often promise to cure many unrelated conditions, charge high out-of-pocket fees, and operate outside FDA oversight. Red flags include vague product descriptions ("amniotic stem cells," "exosomes"), the absence of a ClinicalTrials.gov listing, the absence of imaging guidance, and high-pressure sales tactics. Legitimate options include FDA-regulated clinical trials, Expanded Access programs, and compliant tissue banking services. Patients should always verify claims, ask specific questions, and consult board-certified physicians before paying for any regenerative medicine product or service.
- [Family Eligibility for Banked Adipose Tissue: Regulatory Guidelines for First-Degree Relatives](https://savemyfat.com/family-eligibility-for-banked-adipose-tissue/): One of the most common questions people ask about adipose tissue banking is whether their family members could potentially use their banked adipose tissue in the future. It is a reasonable question, and the answer involves both biology and regulation. Adipose-derived stem cells (ADSCs) collected from your own tissue are inherently autologous, meaning the donor-matching and rejection concerns that apply to allogeneic tissue do not arise in the same way when the tissue is used by the same individual. But what about your parents, your children, or your siblings?
- [Mesenchymal Stem Cells 101: How Adipose‑Derived Cells Compare with Bone Marrow and Birth Tissue](https://savemyfat.com/mesenchymal-stem-cells-101-how-they-compare/): Mesenchymal stem cells, often abbreviated MSCs, are a family of multipotent cells found in bone marrow, adipose (fat) tissue, umbilical cord, and other tissues throughout the body. These cells can differentiate into bone, cartilage, and fat under laboratory conditions and are being studied in hundreds of clinical trials for their regenerative and immunomodulatory properties. Each tissue source offers distinct advantages and tradeoffs that shape how researchers approach different applications.
- [How to Find Legitimate Clinical Trials In 2026 (Including Stem Cell Studies) Without Getting Scammed](https://savemyfat.com/how-to-find-legitimate-clinical-trials-in-2026/): Clinical trials are the primary way new therapies are tested and the only pathway to FDA approval for new drugs and biologics. Many patients with serious or chronic conditions now search for trials on their own, and the volume of information online, especially around stem cell therapies, can make it difficult to distinguish legitimate research from misleading marketing. This guide shows how to use trusted registries, understand trial phases and listings, and avoid unregulated offerings that pretend to be research.
- [Expanded Access Programs: How Patients Can Legally Access Investigational Therapies](https://savemyfat.com/expanded-access-programs-how-patients-can-legally/): Expanded Access, sometimes called compassionate use, is the FDA's formal pathway for certain patients with serious or immediately life-threatening diseases to access investigational products outside of clinical trials when specific criteria are met. It is a regulated, structured process governed by federal law, and it is distinct from both clinical trials and "Right-to-Try" legislation. This guide explains how Expanded Access works, who qualifies, and what patients and providers need to know.
- [How Adipose Tissue Banking Works: The Complete Process from Collection to Cryopreservation](https://savemyfat.com/how-adipose-tissue-banking-works-the-complete/): If you have decided to explore adipose tissue banking, one of the first questions is practical: what does the process actually involve? This guide walks through every step, from the initial consultation to long-term cryogenic storage and potential future retrieval, using published research and clinical trial protocols to explain what happens at each stage.
- [The Science of Adipose Tissue: Why Fat Is More Than You Think](https://savemyfat.com/the-science-of-adipose-tissue-why-fat-is-more/): For most of the 20th century, scientists viewed body fat as a passive energy storage compartment, biologically inert tissue whose only role was to stockpile calories. That understanding changed dramatically starting in the 1990s with the discovery of leptin and the realization that adipose tissue is a complex, biologically active organ. This guide explores the science of fat from the inside out, covering its multiple cell types, its endocrine functions, its role as a stem cell reservoir, and why these properties matter for regenerative medicine research and tissue banking.
- [Adipose Tissue Cryopreservation Viability: What 80 to 90% Post-Thaw Survival Really Means](https://savemyfat.com/adipose-tissue-cryopreservation-viability/): If you have been researching adipose tissue banking, you have probably come across viability percentages like "80 to 90% post-thaw survival" and wondered what those numbers actually mean for you. Those figures come from peer-reviewed studies measuring how many adipose-derived stem cells (ADSCs) survive the cryopreservation process, and they represent some of the most encouraging data in tissue preservation science. But what do they really tell you about the future usefulness of your banked tissue?
- [How Cryopreservation Works: The Science of Freezing and Storing Adipose Tissue](https://savemyfat.com/how-cryopreservation-works-the-science-of-freezing/): Cryopreservation is the scientific process that makes adipose tissue banking possible. Rather than simply freezing fat, cryopreservation uses protective agents and controlled cooling rates to preserve living cells for potential future use. This guide explains what happens at the cellular level during freezing, what protocols are used, what the published viability data shows, and what patients should understand before banking tissue.
- [Birth Tissue vs. Adipose-Derived Stem Cells: What Patients and Providers Need to Know](https://savemyfat.com/birth-tissue-vs-adipose-derived-stem-cells/): Patients and providers exploring stem cell banking options will encounter several different tissue sources, from cord blood collected at birth to fat tissue collected at any point in adulthood. Each source has distinct biological characteristics, regulatory classifications, and practical trade-offs. This guide compares birth tissue stem cell sources and adipose-derived stem cells (ADSCs) side by side, covering biology, cell yield, regulatory status, and what the differences mean for tissue banking decisions.
- [Bone Marrow vs. Adipose-Derived Stem Cells: What Patients and Providers Need to Know](https://savemyfat.com/bone-marrow-vs-adipose-derived-stem-cells/): If you have been reading about stem cells, you have probably come across two sources mentioned more than any other: bone marrow and fat tissue. Both contain mesenchymal stem cells, but the comparison between bone marrow vs. adipose stem cells reveals meaningful differences in how many cells each source provides, how they are collected, and how they behave in the lab. This guide breaks down those differences so patients and providers can make informed decisions about tissue banking options.
- [Red Flags: How to Spot Unethical Stem Cell Clinics and Protect Yourself](https://savemyfat.com/how-to-spot-unethical-stem-cell-clinics/): Q: Are overseas stem cell clinics more dangerous? A: Regulations vary widely by country. Some regions have significantly less regulatory oversight than the United States, meaning products may not undergo the same safety testing, manufacturing quality controls, or physician credentialing standards. Patients who travel abroad for treatment may also have limited legal protections and less access to follow-up care if complications arise. This does not mean every international clinic is unsafe, but the risks can be harder to evaluate.
- [What Are Adipose-Derived Stem Cells? A Patient’s Guide to the Science Behind Your Fat](https://savemyfat.com/what-are-adipose-derived-stem-cells-a-patients-guide/): If you have ever wondered what makes body fat more than just stored energy, you are not alone. Scientists have found that fat tissue holds a surprising number of special cells called stem cells, and researchers around the world are studying them. This guide explains what adipose-derived stem cells are, where they come from, how they compare to other stem cell types, and what this means for people thinking about adipose tissue banking.
- [What Are Clinical Trials for Regenerative Medicine? How Banked Adipose Tissue May Participate](https://savemyfat.com/what-are-clinical-trials-for-regenerative-medicine/): If you have been reading about regenerative medicine and wondering whether clinical trials could eventually involve your own stored tissue, you are not alone. This guide explains what clinical trials are, how they work across each phase, where adipose-derived cell research stands today, and how banked adipose tissue may or may not fit into future trial participation. Clinical trials are research studies, not guaranteed treatments, and banking tissue is a form of preparation, not a promise of access or benefit.
- [What Happens to Your Adipose Tissue After Banking? Storage, Retrieval, and Future Access](https://savemyfat.com/what-happens-to-your-adipose-tissue-after-banking/): If you have banked your adipose tissue or are considering doing so, one of the biggest questions on your mind is probably, "What happens next?" This guide walks you through the full post-banking journey, from how your tissue is stored and monitored to how retrieval works, who owns your tissue, and what future access might realistically look like.
- [Adipose-Derived Stem Cells vs. Bone Marrow Stem Cells: What’s the Difference?](https://savemyfat.com/adipose-derived-stem-cells-vs-bone-marrow-stem-cells/): TLDR: Adipose tissue yields roughly 500 times more mesenchymal stem cells per volume than bone marrow and requires a less invasive collection procedure (under 30 minutes with local anesthesia vs. 30 to 60 minutes under general or spinal anesthesia). Adipose-derived cells also proliferate faster in culture and show minimal age-related decline. However, neither source has FDA-approved disease treatments based on cell source alone, and biological advantages do not automatically determine clinical outcomes. Read the full guide for detailed comparison data.
- [How Does Adipose Tissue Cryopreservation Work?](https://savemyfat.com/how-does-adipose-tissue-cryopreservation-work/): If you're curious about what actually happens when adipose tissue is preserved for long-term storage, you're asking the right question. Understanding the science behind cryopreservation helps you evaluate whether tissue banking aligns with your health planning goals. This guide walks you through the validated protocols, equipment, and quality control measures that make long-term tissue preservation possible, giving you the clarity to make informed decisions.
- [Understanding FDA Regulations for Adipose Tissue: Section 361 vs. 351 HCT/P Pathways Explained](https://savemyfat.com/understanding-fda-regulations-for-adipose-tissue/): If you have ever wondered how the FDA regulates adipose tissue banking, you are not alone. The regulatory framework that governs how fat tissue is collected, processed, and stored in the United States is complex, and understanding it is essential for making informed decisions. This guide breaks down the two primary regulatory pathways, Section 361 and Section 351, explains the four criteria that determine how adipose tissue products are classified, and shows you why these distinctions matter for both patients and healthcare providers. By the end, you will have a clear understanding of how FDA regulations shape the landscape of adipose tissue banking and regenerative medicine.
- [Is Adipose Tissue Banking Safe? What You Need to Know About Cryopreservation Safety](https://savemyfat.com/what-you-need-to-know-about-cryopreservation-safety/): If you are researching adipose tissue banking, one of the first questions on your mind is likely about safety. This guide covers every stage of the banking process, from tissue collection through long-term cryopreservation, so you can evaluate the risks and benefits with confidence. By the end, you will understand what validated safety protocols look like, what complication rates the research shows, and what questions to ask before moving forward.
- [What Is Adipose Tissue Banking? A Complete Guide to Fat Preservation for Future Regenerative Medicine Options](https://savemyfat.com/what-is-adipose-tissue-banking-a-complete-guide/): If you have been exploring ways to prepare for the future of regenerative medicine, understanding adipose tissue banking is a smart place to start. This guide explains how adipose tissue (body fat) is collected, processed, and cryopreserved for potential future use in FDA-regulated clinical research, Expanded Access programs, or approved therapies. You will learn how the banking process works, what the FDA says about regenerative medicine products, and how to tell the difference between legitimate tissue preservation and unproven treatments. By the end, you will have the clarity you need to make an informed decision.
- [Adipose Tissue Banking vs. Stem Cell Treatment Clinics: Understanding the Critical Difference](https://savemyfat.com/adipose-tissue-banking-vs-stem-cell-treatment-clinic/): Regenerative medicine is generating tremendous interest, but the gap between legitimate science and aggressive clinic marketing has never been wider. This guide breaks down the differences between adipose tissue banking and stem cell treatment clinics, explains how the FDA regulates each, and gives you tools to protect yourself. By the end, you will understand regulatory pathways, recognize red flags, and know what questions to ask.
- [How Long Can Adipose Tissue Be Cryopreserved? What the Science Says](https://savemyfat.com/how-long-can-adipose-tissue-be-cryopreserved/): TLDR: Peer-reviewed studies show adipose tissue can be cryopreserved for years while retaining meaningful cell viability. Storage in liquid nitrogen at negative 196 degrees Celsius effectively halts all biological activity indefinitely. Research documents successful cell recovery after eight or more years of storage, with post-thaw viability rates of 80 to 90 percent. However, banking tissue does not guarantee future treatment access or clinical benefit. Read on for the complete scientific picture.

## Pages
- [Knowledge Base](https://savemyfat.com/knowledge-base/): SaveMyFat connects you with a U.S.-based tissue bank so you can preserve your own adipose (fat) tissue today. It stays documented and available in case you and a licensed physician ever explore a future FDA-regulated pathway. Banking is preservation, not treatment.
- [Oscar Tellez](https://savemyfat.com/oscar-tellez/): Oscar Tellez is the founder and CEO of SaveMyFat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. Oscar has spent more than a decade working across the regenerative medicine industry, including product distribution, laboratory and vendor relationships, and provider training. He founded SaveMyFat to connect patients and providers with compliant adipose tissue banking and to simplify the process. This article is educational, reflects current FDA guidance, and is not medical advice or a substitute for consultation with a licensed clinician.
- [Adipose Tissue Banking and Longevity](https://savemyfat.com/longevity-and-tissue-banking/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Compliant Marketing Standards for Regenerative Medicine](https://savemyfat.com/compliant-marketing-standards/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Adipose and Stem Cell Science Glossary](https://savemyfat.com/stem-cell-science-glossary/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Physician Resource Center for Adipose Tissue Banking](https://savemyfat.com/physician-resource-center/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Adipose-Derived Stem Cell Clinical Trials: A Directory by Condition](https://savemyfat.com/adipose-stem-cell-clinical-trials/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [State Stem Cell Laws and Disclosure Rules: A Guide by State](https://savemyfat.com/state-stem-cell-laws/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [FDA Regulation of Adipose Tissue and Stem Cells: A Complete Guide](https://savemyfat.com/fda-regulation-adipose-tissue/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Providers Sign Up](https://savemyfat.com/providers-sign-up/): We Send You Patients Patients searching for stem cell banking in your area get connected directly to your practice..
- [Accessibility Statement](https://savemyfat.com/accessibility-statement/): Save My Fat LLC is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards.
- [Disclaimer](https://savemyfat.com/disclaimer/): IMPORTANT: BY USING THIS WEBSITE (https://savemyfat.com), YOU ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS DISCLAIMER. IF YOU DO NOT AGREE TO THESE TERMS, YOU MUST NOT USE THIS WEBSITE.
- [Cookie Policy](https://savemyfat.com/cookie-policy/): 1. IntroductionThis Cookie Policy ("Policy") explains how Save My Fat LLC ("Company", "we", "us", or "our") uses cookies and similar tracking technologies (pixels, web beacons, local storage) when you visit our website, https://savemyfat.com (the "Site").
- [Privacy Policy](https://savemyfat.com/privacy-policy/): Read our privacy policy here.
- [Terms and Conditions](https://savemyfat.com/terms-and-conditions/): Arbitration In the event the parties are not able to resolve any dispute between them arising out of or concerning these Terms and Conditions, or any provisions hereof, whether in contract, tort, or otherwise at law or in equity for damages or any other relief, then such dispute shall be resolved only by final and binding arbitration pursuant to the Federal Arbitration Act, conducted by a single neutral arbitrator and administered by the American Arbitration Association, or a similar arbitration service selected by the parties, in a location mutually agreed upon by the parties. The arbitrator's award shall be final, and judgment may be entered upon it in any court having jurisdiction. In the event that any legal or equitable action, proceeding or arbitration arises out of or concerns these Terms and Conditions, the prevailing party shall be entitled to recover its costs and reasonable attorney's fees. The parties agree to arbitrate all disputes and claims in regards to these Terms and Conditions or any disputes arising as a result of these Terms and Conditions, whether directly or indirectly, including Tort claims that are a result of these Terms and Conditions. The parties agree that the Federal Arbitration Act governs the interpretation and enforcement of this provision. The entire dispute, including the scope and enforceability of this arbitration provision shall be determined by the Arbitrator. This arbitration provision shall survive the termination of these Terms and Conditions.
- [Adipose Stem Cell Research Areas | Conditions Being Studied](https://savemyfat.com/stem-cell-research-areas/): Researchers worldwide are studying adipose-derived stem cells for conditions with limited treatment options. Many trials are happening right now in the United States.
- [Family Stem Cell Banking | SaveMyFat](https://savemyfat.com/family/): When you bank your stem cells with Save My Fat, you are not just investing in yourself. Under certain guidelines, your spouse, children, and parents may also be eligible to use your banked cells. In some cases, second-degree relatives like siblings may qualify too. 
- [Emerging Adipose Stem Cell Research in 2026 | SaveMyFat](https://savemyfat.com/emerging-research/): Science in the Stem Cell industry is rapidly evolving. Banking your cells now means possible access to future treatments as they become available.
- [How Adipose Tissue Banking Works | SaveMyFat](https://savemyfat.com/how-stem-cell-banking-works/): Stem cell banking starts with a quick visit to a SaveMyFat partner provider. In less than 20 minutes, a small amount of fat is collected and shipped
- [Stem Cell Banking for Longevity & Healthy Aging | SaveMyFat](https://savemyfat.com/wellness-and-healthy-aging/): Your body's ability to repair and regenerate slows down over time. Energy fades. Recovery takes longer. The resilience you once had becomes harder to maintain.
- [Adipose Banking for Joint & Orthopedic Health | SaveMyFat](https://savemyfat.com/joint-and-orthopedic/): Pain medication masks symptoms but does not fix the problem. Cortisone shots wear off after a few weeks. Physical therapy helps but...
- [Our Blog](https://savemyfat.com/our-blog/)
- [Adipose Banking Pricing & Plans | SaveMyFat](https://savemyfat.com/pricing/): One procedure covers everything: harvest, lab processing, long-term cryopreservation, and your first treatment, plus hundreds of vials banked for future use.
- [Bank Your Fat Stem Cells | Patient Guide](https://savemyfat.com/patients/): Pain medication masks symptoms but does not fix the problem. Cortisone shots wear off after a few weeks. Physical therapy helps but only goes so far. Surgery does not...
- [Join SaveMyFat’s Provider Network | Physicians](https://savemyfat.com/providers/): Regenerative medicine demand is growing. Your patients are researching stem cells, asking about alternatives...
- [About SaveMyFat | Adipose Tissue Banking Company](https://savemyfat.com/about-us/): Save My Fat helps you preserve your own adipose tissue today so it may be available for carefully regulated medical opportunities in the future.
- [Contact SaveMyFat | Find a Provider or Partner](https://savemyfat.com/contact-us/): Looking to bank your cells? Find a provider. Ready to offer stem cell banking? Join our network.
- [Bank Your Fat Stem Cells Today | SaveMyFat](https://savemyfat.com/): Most people have never heard of adipose-derived stem cells. But the science is clear: your fat tissue is one of the richest sources of regenerative cells in your entire body.

## Categories
- [Adipose](https://savemyfat.com/category/adipose/)
- [Adipose Banking](https://savemyfat.com/category/adipose-banking/)
- [Birth Tissue](https://savemyfat.com/category/birth-tissue/)
- [Bone Marrow](https://savemyfat.com/category/bone-marrow/)
- [Clinical Trials](https://savemyfat.com/category/clinical-trials/)
- [Cryopreservation](https://savemyfat.com/category/cryopreservation/)
- [Exosomes](https://savemyfat.com/category/exosomes/)
- [Medical Tourism](https://savemyfat.com/category/medical-tourism/)
- [Providers](https://savemyfat.com/category/providers/)
- [Regulation](https://savemyfat.com/category/regulation/)
- [Stem Cells](https://savemyfat.com/category/stem-cells/)

## Markdown

Every page on this site is available as markdown. Append `?output_format=md` to any URL, add a `.md` suffix, or send an `Accept: text/markdown` request header.